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ABSTRACT 
 
CLINICAL TRIAL OF COGNITIVE-BEHAVIORAL THERAPY TO REDUCE 
ANTIRETROVIRALSIDE EFFECTS IN HIV PATIENTS 
 
 
 
By 
R. Eric Doerfler 
December 2010 
 
Dissertation supervised by Linda Goodfellow, PhD, RN 
 Antiretroviral therapy (ART) for HIV/AIDS has led to significant improvements 
in survival and a reduction in AIDS-related morbidity. Adherence to regimens is vital, yet 
clinical observations and research have suggested that side effects are a significant reason 
for non-adherence. This randomized, controlled clinical trial was a pilot study sought to 
determine if a brief exposure cognitive-behavioral therapy (CBT) could reduce side effect 
symptoms in HIV/AIDS patients on ART. Methods: 33 participants were randomized to 
standard adherence education alone or adherence education plus three sessions of CBT 
over a period of three months. Results: Completing the study were 17 males and one 
female; whites, blacks, and Hispanics were represented in the sample. Mean duration of 
ART was over 200 weeks. Participants in the experimental group reported significantly 
less nausea and fatigue, compared to those in the control group (Mann-Whitney U, p < 
v 
 
.05). There were no differences in adherence across the study, which was reported at 
>94%. No differences in CD4 lymphocyte counts or viral load were observed between 
groups over the course of the study. Observations suggested that scheduling visits with 
the psychologist delivering the CBT sessions was an obstacle to continued participation. 
The use of side effect reducing medication was low in both groups. Increasing daily 
practice sessions was correlated with an increase in reported nausea scores. The reason 
for this observation is not known. Brief exposure to CBT training in male HIV/AIDS 
patients on ART appears to reduce side effect symptoms. A larger sample with more 
female representation is warranted to further explore this intervention Referral for CBT to 
reduce side effect symptoms in similar patients may be warranted. 
  
vi 
 
DEDICATION 
 This research is dedicated to the late poet Stephen R. Norris, and to my wife, Julie 
Moffitt, for her patience and support during the process. 
  
vii 
 
ACKNOWLEDGEMENTS 
 I would like to acknowledge Dr. John Zurlo, Nurse Daphne Greenawalt, and the 
rest of the Caring Together team, the patients who participated in this study, as well as 
the staff at the Infectious Disease Clinic at the Penn State Milton S. Hershey Medical 
Center, for their assistance in making this research possible. Funding for this study was 
provided by Penn State Harrisburg and the Beta Sigma Chapter of Sigma Theta Tau 
Nursing Honor Society (Penn State School of Nursing, State College, PA). Special thanks 
to Cinda Boyer (Special Hematology Lab) and Nate Sheaffer (Cell Science Core Facility) 
at the Penn State Milton S. Hershey Medical Center for their technical assistance. Thanks 
to Dr. Kathrine Bakke-Friedland for her assistance during independent study for project 
planning and intervention design, and to Paul Ricci for statistical consultation. Thanks to 
the Penn State School of Nursing and Dr. Mary Beth Clark for providing facilities for the 
behavioral intervention. Finally I would like to acknowledge my Dissertation Committee, 
Drs. Linda Goodfellow and Mary Ann Thurkettle of Duquesne University, and Dr. 
Suzanne Willard of the Elizabeth Glaser Pediatric AIDS Foundation, for their guidance, 
tireless work, and assistance with this project. 
  
viii 
 
TABLE OF CONTENTS 
Page 
Abstract .…….…….……………………………………………………………………...iv 
Dedication ..…….……………………………………………………….………………..vi 
Acknowledgements……………………………………………………….……………...vii 
List of Tables ...………………………………………………………...………………...xi 
List of Figures ...……………………………………………………………...…….……xii 
1     Statement of the Problem                1 
Introduction……………………………………………………...…………………….1 
 Research Questions and Hypotheses…………..……………………………………..2 
Assumptions Underlying the Research…………………………………………..........3 
Definition of Terms………………………………………………………………...….3 
Theoretical Framework……………..………………………………………………...6 
Significance to Nursing…………………..…………………………………………...8 
Summary……………..……………………………………………………..………..10 
2    Literature Review                11 
Three Historical Periods of HIV Management…………….…….…………………..11 
Immunobiology of HIV………………………………….…………….…………….12 
Antiretroviral Therapy and its Implications……………..……………………….…..18 
Antiretroviral Resistance and Adherence……………………………………………18 
Educating Patients for Antiretroviral Therapy…………………….…………………22   
Cognitive-Behavioral Therapy for Symptom Management……..….…. ……..….…27 
Antiretroviral Therapy and Cognitive-Behavioral Therapy…………………...…….36 
ix 
 
Gaps in the Literature……………………………………….………………….…….44 
Summary…………………………………………………………………….….…....44 
3    Methods                  46 
Research Design…….....……………………………………………………………..46 
Setting………...……………………...………………..……………………………..46 
Sample………..…...……………………………………………………………….…47 
Eligibility Measures.………...…………………………………………………….…47 
Subjective Health Measures……………………………..…………….……….…….48 
Adherence Measures……………………………………………...………………….54 
Control Measures………………………………………………………...…………..56 
Immunologic Measures…………………………………………………...………….57 
Standard of Care and Experimental Intervention………………………...……….….59 
Procedures for Data Collection………………………………………………………65 
Ethical Considerations…………………………………………………………….....68 
Data Analysis………………………………………………………………………...70 
Summary………………………………………………………………………….….73 
4    Results and Data Analysis               75 
Recruitment and Study Completion………………………………………………….75 
Description of the Sample……………………………………………………………77 
Analysis of the Sample for Statistical Testing……………………………………….80 
Hypothesis Testing…………………………………………………………………...81 
Summary of Data Analysis…………………………………………………………..93 
 
x 
 
5    Discussion and Implications              95 
Discussion of Results………………………………………………………………...95 
Limitations of the Study……………………………………………………………..98 
Premise of the Study and Issues in Recruitment of Participants………………….....99 
Theoretical Framework…………………………………………………………….101 
Suggestions for Future Research…………………………………………………...103 
Implications for Nursing Practice…………………………………………………..104 
Conclusions…………………………………………………………………………105 
References………………………………………………………………………………107 
Appendix A Demographic Data Form...………………………………………………..131 
Appendix B Measurement Instruments……...…………………...…………………….132 
Appendix C Recording Sheets for the Use of SERM ….………………………………147 
Appendix D Informed Consent…………………………………………………………151 
Appendix E Confidentiality Agreement……...………………………………………...158 
xi 
 
LIST OF TABLES 
Page 
 
1.1 Nursing Diagnoses in ART…………………………………………………….....9 
2.1 Studies of Cognitive-Behavioral Therapy in Antiretroviral Therapy…………...43 
3.1 Symptom Variables……………………………………………………………...48 
3.2 SF-36 Scoring System…………………………………………………………..54 
3.3 Data Collection Plan…………………………………………………………….68 
3.4 Dependent and Confounding Variables…………………………………………71 
4.1 Summary of Enrollees and Withdrawals………………………………………...76 
4.2 Demographic Composition of the Sample………………………………………77 
4.3 Descriptive Statistics of the Total Sample………………………………………78 
4.4 Group Comparison, Independent Samples Test…………………………………79 
4.5 Symptom Scores: Mean Skewness and Kurtosis………………………………..81 
4.6 Test of Hypothesis 1: Before Imputation Analysis………………..…………….84 
4.7 Test of Hypothesis 1: After Imputation Analysis...………………..…………….85 
4.8 Correlations Between Measures for Adherence…..………...…….……………..87 
4.9 Participant-estimated Adherence by VAS, Group Differences………………….88 
4.10 Descriptive Statistics of Raw Laboratory Data…………….……..……………..88 
4.11 Descriptive Statistics: CD4 Means Compared Before and After Imputation…...89 
4.12 Descriptive Statistics: Viral Load Means Compared Before/After Imputation…90 
4.13 Correlations Between Average Daily Practice and VAS Symptom Scores…….93 
xii 
 
LIST OF FIGURES 
Page 
2.1 Life Cycle of HIV……………………………………………………………….14 
2.4 Idealized Model of T-cell Activity……………………………………….……...17 
3.1 Study Scheme……………………………………………………………………67 
4.1 Summary of Recruitment and Retention………………………………………...76 
4.2 Weeks on Antiretroviral Therapy at Study Entry…………………………….….87 
4.4 Side Effect Reducing Medication Use During the Study……………….….……92 
 
 1 
 
Chapter 1 
Statement of the Problem 
Introduction 
Side effects can occur from the use of any drug. Patients who have human 
immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) 
related to HIV follow a similar course of treatment similar to that of the cancer patient 
undergoing chemotherapy. As with all medicines, antiretroviral treatment (ART) for 
HIV/AIDS may result in side effects that limit patients’ ability to continue treatment 
Clinically, the researcher has listened to HIV/AIDS patients on ART describe feeling ―toxic‖ 
or ―sick on the meds.‖  
Those with HIV who are on ART may miss medication doses or discontinue the 
regimen for various reasons. Reasons for non-adherence include substance abuse, 
forgetfulness, scheduling difficulties and lifestyle interference, and misconceptions about the 
use of the elements of ART. A significant reason for discontinuation is side effects, including 
side effects not responsive or only partially responsive to anti-side effect medications 
(Bartlett, 2002; Chesney, 2000, 2003; Laws, Wilson, Bowser, & Kerr, 2000). An anecdotal 
observation is that despite treatment with side effect reducing medications (SERM) some 
patients’ symptoms grow worse. Patients on ART have made statements such as, ―I know this 
is all in my head.‖ Thus, some patients seem to understand that their own mental framing of 
ART can influence their experience of side effects. Based on oncology literature the author 
referred a few such patients to a cognitive-behavioral therapist for help controlling side 
effects and anxiety. The researcher’s request at the time was for the therapist to provide 
cognitive-behavioral therapy (CBT) to help those patients reframe the experience of ART and 
 2 
 
to teach them techniques for reducing anxiety and emotional arousal associated with that 
experience. In this very small series of patients, two went on to successful ART with 
moderated side effects and an improved ability to sustain adherence to their regimens over 
time. This clinical anecdotal experience, in addition to studies reported in the oncology and 
psychological literature, are the bases for this study. 
Questions 
 The present study examined whether CBT can help to reduce the discomfort of side 
effects in ART. It was hypothesized that a reduction of side effects might alter how patients 
adhere to their regimens. Finally, it was further hypothesized that if patients adhere better, 
there might be changes in serum levels of HIV, and CD4 lymphocyte counts. This led to the 
following questions for study: 
 Will a CBT intervention reduce side effects (nausea, pain, fatigue, and/or anxiety) in 
HIV patients undergoing ART compared to patients who only receive education on 
proper adherence to medication (standard of care [SOC])? 
 What is the relationship between measured side effects and self-reported adherence? 
 What is the relationship between measured side effects and clinical measures (CD4+ 
lymphocyte [CD4] counts and serum viral burden [―viral load,‖ VL])?  
Hypotheses 
 Participants who receive the CBT intervention will report a reduction in side effects, 
compared to participants who only receive the SOC. 
 Participants who receive the CBT intervention will show a difference in adherence 
compared to those who only receive the SOC. 
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 Participants who receive the CBT intervention will show a difference in CD4 and VL 
compared to those who only receive the SOC. 
Assumptions Underlying the Research  
 Methodological assumptions underlying the research were: 
 Study participants were honest in their symptom reporting, as well as how they felt 
mentally and physically. 
 Participants were able to make reliable estimates of symptom intensity and duration, 
and faithfully marked the instruments thus. It was assumed that participants would not 
hurry through the questions, nor hastily mark answers in order to ―get through‖ the 
questions quickly. 
 Laboratory data from various laboratories is standardized. A detailed discussion of 
laboratory methods and standardization appears in Chapter 3. 
Definition of Terms  
Adherence.  Patients’ ability to continue on a medication or other treatment regimen 
is generally subsumed under the rubric of ―compliance‖ or its more recent phrasing 
―adherence.‖ Alternative ways of defining compliance recognize patient participation in 
clinical decisions, with clinicians serving as expert advisers (Vermeire, Hearnshaw, Van 
Royen, & Denekens, 2001), and ―adherence‖ has become popular (Dunbar, 1980; Lieberman, 
1996). The terms are often used interchangeably, but adherence is the term of choice among 
treatment professionals in HIV disease. Adherence in this study was measured as the 
percentage of doses taken, according to the regimen, based on patient recall, recorded on the 
VAS and proportion of doses taken in three days, a measurement known as ―three-day 
recall‖. The use of VAS in adherence measurement in HIV is discussed under methodology.   
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Antiretroviral therapy. Antiretroviral therapy is the use of a minimum of two 
antiretroviral drugs with the aim of reducing serum viral nucleic acids below the limits of 
detection. Most commonly, at least three agents from at least two different classes of 
antiretroviral drugs form the basis for any regimen (Panel_on_Antiretroviral_Guidelines_for_ 
Adults_and_Adolescents, 2009)  
Clinical endpoints. Clinical Endpoints were measured by CD4+ lymphocyte subset 
(―CD4 count‖) and serum HIV nucleic acids (―viral load‖) which are the standard measures, 
termed clinical endpoints, in HIV/AIDS treatment centers (Fahey et al., 1990). CD4 count 
and viral load were measured at two time points, at the beginning and at the end of subject 
participation in the study. Only results from samples within 30 days of the beginning of the 
study (first measurement) or end of the study (last measurement) were used. 
 Cognitive-behavioral therapy (CBT). In this study, CBT is defined as a system of 
psychological treatment based on the understanding of a patient’s beliefs and thoughts, which 
drive their experience. In CBT theory, so-called automatic thinking contributes to discomfort 
or psychological distress. In CBT the patient’s thoughts are reframed through discussion and 
education. Adjunctive techniques to reduce arousal aid this process. Such techniques include 
relaxation, guided imagery, biofeedback, and other methods (A. T. Beck, 1976). 
 Side effect symptoms. In this study there are two types of symptoms to consider. The 
first type of symptom signals some potentially serious problem such as anemia, lactic 
acidosis, or peripheral neuropathy. The second type of symptom includes sensations that are 
bothersome, but do not necessarily demand a change of regimen or other medical 
intervention. Several of the symptoms that this study examined fit into both categories. 
Serious problems were ruled out by the usual clinical follow up, just as in normal practice. 
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Once serious problems were ruled out, what remained were the persistent, troublesome, 
wearying symptoms that were the focus of this study: nausea, fatigue, pain, and anxiety. The 
terms discomfort and comfort are defined as the presence or absence of those four symptoms, 
and are also related to the domain scores of the Short Form-36 (SF-36). 
Nausea. Nausea is defined as an unpleasant sensation localized to the abdomen. In 
vernacular terms it is also described as ―queasiness,‖ or being ―sick in the stomach‖ (NCCN, 
2005). The perception of duration of nausea, its average perceived intensity, and its greatest 
perceived intensity were measured by VAS at four time points.   
Pain. In this study, pain is unpleasant sensation rooted in nociception that may or may 
not be related to tissue damage (Joffe & Sandler, 1967; Merskey & Spear, 1967). Pain may 
be malignant or non-malignant, and other than ruling out life threatening causes, the cause of 
the pain was not considered. The perception of duration of pain, its average perceived 
intensity, and its greatest perceived intensity were measured by VAS at four time points.  
Pain over the last four weeks was also be measured by verbal intensity scaling (Item 7) in the 
Short Form-36, at four time points. 
Fatigue. Hart, Freel, and Milde (1990) defined fatigue as ―a subjective self-evaluation 
of sensations associated with discomfort, decreased motor and mental skill and increased task 
aversion‖ (pp.967-968). Tack (1990), looking at fatigue reported by rheumatoid arthritis 
patients described it as, ―the subjective sensation of generalised tiredness or exhaustion‖ (p. 
154). The perception of duration of fatigue, its average perceived intensity, and its greatest 
perceived intensity was measured by VAS at four time points.  Role performance (RP), 
physical functioning (PF), and vitality, terms operationalized in the SF-36, was also measured 
as behaviors (RP and PF) and sensation (vitality) related to fatigue, at four time points. 
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Anxiety. Whitney (1992) defined anxiety by four critical attributes.  
 There is the presence of a vague, uneasy feeling of discomfort or dread.  
 The source or cause of the anxiety is unknown or nonspecific in origin.  
 Subjective responses that act as energizers (i.e., prompt action) but cannot be 
observed directly are present; these responses may be classified as 
psychological/behavioral.  
 Objective signs that are the result of the transformation of the energy into 
relief behaviors are present; these signs may be classified as physiologic, 
psychological/behavioral, or cognitive.  
The perception of duration of anxiety, its average perceived intensity, and its greatest 
perceived intensity was measured by VAS at four time points.  Role-emotional (RE), social 
functioning (SF), and mental health (MH), terms operationalized in the SF-36, were also 
measured as related to anxiety, at four time points. However, domains such as MH also 
include measurement of items related to depression and other aspects of mood. This is 
considered further in Chapter 5. 
Theoretical Framework  
 The theoretical framework for this study was based on cognitive control of autonomic 
responses. Skinner (1971) suggested the use of consequences to modify behavior (operant 
conditioning), but Pavlov’s original work dealt with classical, also called respondent, 
conditioning. Respondent conditioning is reflexive, intimately coordinated with the 
sympathetic and parasympathetic branches and endocrine function, and targets physical 
responses operated by those systems, chiefly as a means of ensuring that organisms adapt to 
their environment (Rescorla, 2003). Pavlov’s classic example was based on the fact that the 
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presentation of food leads to saliva production. The dog in Pavlov’s experiment was given 
food when a bell was rung. The stimulus of the bell was paired with the stimulus of being 
given food, and an autonomic response was generated. 
Anticipatory nausea and vomiting (ANV) in antineoplastic therapy is one example 
from oncology that exemplifies how conditioning combined with autonomic arousal 
potentiates symptom experience. The nausea and vomiting that may have occurred from a 
first chemotherapy treatment form a stimulus-response pair. The circumstances of the event 
become paired with nausea and vomiting and may elicit the autonomic response without 
actual antineoplastic therapy being administered. A similar-appearing process has been 
observed by the author to occur in patients on ART. In their theoretical analysis of ANV, 
Burish and Carey (1986) noted that there are several theories about how this problem 
develops. Proposed alternative theories with, they argue,  less supporting evidence are 1) 
psychodynamic readjustment to serious illness, 2) attention-seeking behavior, and 3) anxiety-
induced nausea related to as-yet-poorly understood mechanisms in brain and gut tissue. 
Respondent conditioning is essentially classical conditioning, but Burish and Carey note that 
even this generally-accepted theory fails to explain why some people develop conditioned 
responses and others do not, nor why varying numbers of exposures to adverse symptoms 
lead to the conditioned responses in different patients (lending some credence to the 
possibility of alternate explanations). The authors posit an extension of the respondent 
conditioning theory, that such conditioning is mediated by anxiety. 
In this way, the theory selection for this project admits that ART may be a desired 
option, indeed may be understood as necessary and life-saving by the patient. However, the 
emotional reaction to that experience may change patient reactions even though he/she knows 
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such reactions may reduce his or her ability to maintain the treatment. Thus, the theory 
suggests that strategies to reduce anxiety as well as change automatic thinking would be 
beneficial.  
Burish and Carey (1986) propose that anxiety is a key mediating factor in somatic 
symptoms such as ANV and other complaints. From the theoretical perspective in this study, 
CBT offers a means to address several factors at once.  
Cognitive-behavioral therapy proposes that life challenges may be engaged by 
discovering the complaint (e.g., ―I’m anxious about taking my meds.‖) and then to determine 
what maladaptive automatic thinking drives that emotional sensation (A. T. Beck, 1976; J. S. 
Beck, 1995). The goal of CBT is to engage higher cortical function to change the automatic 
thinking, which relieves the emotional sensation. Behavioral techniques serve to gain 
autonomic control (which can also serve to shift the locus of control inward), which in turn 
makes it easier for the patient to assert control over automatic thinking (A. T. Beck, 1976; J. 
S. Beck, 1995; Kalichman, 1995). 
Significance to Nursing 
Schietinger and Daniels (1996) interviewed HIV/AIDS patients on their perceptions 
regarding their health care, and in particular, how they view their health care providers. Of 
the five themes that emerged, one pertinent to the aim of this study is that patients wanted 
their providers to appreciate them holistically, that is with a sense of the importance of their 
psychosocial and spiritual needs, as well as the physical needs. Nurses assess patients for 
potential problems with side effects and adherence (Spirig, Moody, Battegay, & DeGeest, 
2005; Wolfe, 1997). Taking a diagnostic approach (Caetano & Pagliuca, 2006), HIV/AIDS 
patients who undertake ART are at risk for the diagnoses in Table 1.1 
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Table 1.1  
Common Nursing Diagnoses Applicable to Patients on ART 
________________________________________________________________________ 
Acute pain 
Ineffective therapeutic regimen management 
Activity alteration 
Activity intolerance/risk 
Anxiety 
Body nutrition deficit/risk (related to nausea/vomiting) 
Chronic pain 
Fatigue 
Fluid volume deficit/risk 
Instrumental Activities of Daily Living (IADLs) alteration 
Knowledge deficit of therapeutic regimen 
Nausea 
Sleep pattern disturbance 
Swallowing impairment (related to anxiety, with impact on dose consumption) 
Unspecified pain 
________________________________________________________________________ 
The diagnoses in the Table focus on problems related to ART. The Table also does 
not include diagnoses that are unlikely to respond to cognitive-behavioral interventions as 
designed in this study (e.g., progressive muscle relaxation, guided imagery), such as diarrhea 
and/or bowel incontinence, blood pressure alteration and/or respiration alteration. Examples 
of this include anemia due to non-nucleoside reverse transcriptase inhibitors (NRTIs), 
contraceptive risk related to  pregnancy that may occur during occurring during use of 
efavirenz [Sustiva®, Bristol-Myers Squibb, New York]), or tactile alteration from sensory 
loss related to neurotoxic agents such as stauvudine [Zerit®, Bristol-Myers Squibb, New 
York]). 
Pharmacologic therapy of HIV/AIDS has become the mainstay of medical treatment. 
Nursing complements such treatment in several ways. This study concerned itself with a 
possible method nurses may use to complement medical therapy, by helping patients remain 
adherent through the employment of a method which may reduce side effect burden. 
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Summary 
This study was a randomized, controlled clinical trial that compared the use 
CBT/SOC to SOC alone in an attempt to reduce side effect symptoms in HIV/AIDS patients 
on ART. The study also sought to explore whether symptom reductions led to improvements 
in adherence to medical regimens, and further, to greater improvements in CD4 counts and 
viral loads, compared to controls. Standard of care was defined as adherence education and 
side effect monitoring, as currently practiced. Nausea, pain, fatigue, and anxiety as measured 
by VAS at four time points in this multiple measures study, were the main dependent 
variables. Anxiety may potentiate the other three symptoms, as well as serve as a source of 
discomfort itself. The theoretical framework of the study is based on cognitive control of 
autonomic responses. Theory suggests that symptoms such as the four selected for this study 
would respond to a reduction in autonomic arousal. Cognitive therapy and behavioral 
techniques are one means by which patients may access control of arousal, thus leading to a 
perceived reduction of the symptoms under study, and the use of CBT was the independent 
variable in the study. Nurses diagnose the symptoms suffered by HIV/AIDS patients on ART 
and intervene to reduce those symptoms. The study explored the utility of a method by which 
nurses may improve the care and comfort of their patients. 
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Chapter 2 
Review of the Literature 
The Three Historical Periods of HIV Management 
 Clinical HIV disease was detected when several homosexual men, who had no known 
cause of immunodeficiency, were treated for pneumonia caused by Pneumocystis carinii 
(now P. jirovecii), an opportunistic pathogen that only causes disease in the 
immunosuppressed, in 1981; two died (CDC_MMWR, 1981). From the beginning an 
epidemiological pattern suggested an infectious cause was among the hypotheses for this 
acquired immunodeficiency, although there were also many competing hypotheses including 
immunodeficiency induced by abused inhalants such as amyl nitrite, or autoimmunity 
stemming from exposure to spermatozoa. By 1985 the cause of AIDS was elucidated at about 
the same moment in both France and the United States (Sepkowitz, 2001). Disease-causing 
retroviruses were not entirely new. The observation that certain RNA viruses (in which the 
genome is carried in riboxynucleic acid, analogous to a photographic ―negative‖) copied their 
genetic information into host-cell DNA (deoxyribonucleic acid) changed the way biologists 
had always thought about the direction of genetic information transfer (classically, from 
DNA to RNA to protein) (Fauci & Longo, 2001). Since then HIV has infected tens of 
millions throughout the world (Sepkowitz, 2001; UNAIDS, 2006). During the more than 20 
years of the AIDS epidemic, there have been three phases. The first, from 1981 to 1985, 
involved elucidating the cause. The second, from 1985 to 1996, was a period in which all 
attempts at therapeutic success against the virus led to failure, and the infection was 
considered fatal. The third period is from 1996 to today, the age of effective combination 
ART. However, this has not led to the hoped-for ―cure‖ of HIV infection per se. In the next 
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sections, this and related issues will be discussed in terms of the life cycle of HIV, its affinity 
for key immune system component cell types, its viral dynamics and genetic instability, why 
treatment must endure for long periods of time, and how viral genetics may lead to drug 
resistance when patients are unable to adhere to the regimens properly. 
Immunobiology of HIV 
Retrovirus Genetics and the Persistence of HIV Infection. As suggested above, 
retroviruses become a part of the host cell genome. Thus, elimination of an HIV infection 
must also eliminate every infected cell in the host. A detailed discussion of the gene 
sequences in retroviruses is beyond the scope of this paper, but it is important to note one 
feature. This involves the first step in the productive infection of host cells by retroviruses, as 
well as the formation of antigen-specific immune competence. 
Normal Human Immune Responses. Cluster of differentiation (CD) is a set of over 
250 cell surface antigens that act as receptors, ligands, and perform other tasks. The fourth in 
the series, CD4, is a 55 kiloDalton protein chain occurring on certain thymocytes, 
macrophages, and lymphocytes. Major histocompatability complex (MHC; types I and II) on 
host cells contains a small sample of viral peptide which has been derived from within the 
infected host cell to form a supercomplex that comes into contact with a T-cell receptor 
(TCR). The signal that results from this sequence of events triggers the CD4 lymphocyte to 
activate macrophage killing of bacteria, and B-lymphocytes to differentiate and produce 
antigen-specific immunoglobulins. Macrophages are a major cell subset in immunity to 
bacterial infection. Immunoglobulins help to provide immunity to viral infections and to 
neutralize bacterial and other toxins (Janeway, Travers, Walport, & Shlomchik, 2005).  
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Retroviruses Downregulate Normal Human Immunity. The lentivirus family of 
retroviruses, and especially HIV, contain a coding sequence, nef (negative-regulation factor), 
which downregulates CD4, and since this is a key component of the MHC/TCR complex and 
serves as the cellular receptor for HIV, T-lymphocyte activation pathways are altered, 
affecting immune system function downstream (Fauci & Longo, 2001; Janeway, et al., 2005). 
HIV. An encapsulated virus approximately 100nm in diameter, HIV contains a 9.7 
kilobase (kb) genome consisting of three major structural genes, including the reverse 
transcriptase (RT) gene—the gene that makes a retrovirus what it is, enabling HIV to ―write 
itself into‖ the genes of host cells for which it is tropic (Streicher, Reitz, & Gallo, 2000).  
The virus fuses with the host cell via the gp120/gp41 complex on its lipid membrane; 
the complex itself binds with CD4. For entry, the virus uses one of two co-receptors  located 
on cell membranes, CCR5 (on T-cells, macrophages and microglia) (Choe et al., 1996; He et 
al., 1997; Lederman, Penn-Nicholson, Cho, & Mosier, 2006) and CXCR4 (on T-cells) 
(Berger, Murphy, & Farber, 1999). Small changes in the V3 loop of gp120 direct whether a 
particular strain will target CCR5 or CXCR4 receptor types.  
Following fusion, the virus core enters the cytosol, at which time free viral RT 
enables incorporation of the viral genome into host cell DNA (integration). T-cell activation 
seems to be required for viral disassembly and the fusion of additional viral particles 
(Cleghorn, Reitz, Popovic, & Gallo, 2005; Gowda, Stein, Mohagheghpour, Benike, & 
Engleman, 1989). Viral positive-stranded RNA is transcribed into nuclear DNA—even in 
resting cells, and it is believed that this is one of the means by which HIV reservoirs may 
remain stable for extremely long periods (years or even decades) in resting T-lymphocytes, 
monocytes, and macrophages (Cleghorn, et al., 2005).  
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Later, when cells undergo division, as in response to clonal expansion following an infection 
to which CD4+ lymphocytes respond, virus is produced as well, using host cell regulating 
enzymes (transcription) (Streicher, et al., 2000). However, active cell division is not required, 
as viral production occurs even when cells are not actively mitotic (Graziosi et al., 1993). 
After new viral proteins are generated, viral proteases cleave the new strand of protein, and 
other enzymes assemble the virus for budding from the cell surface (Streicher, et al., 2000) 
Figure 2.3 depicts the life cycle of HIV and displays multiple drug targets at the fusion, 
reverse transcription,  integration and protease production stages.  
 
   Figure 2.1 Life cycle of HIV.  
 
 
Figure 2.3. Antiretrovirals target binding, fusion, reverse transcription, proviral 
integration, and early assembly. From Cleghorn, Reitz, Popovic, and Gallo (2005). 
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Ho et al. (1995) showed that daily HIV production is quite high. Perelson, Neumann, 
Markowitz, Leonard, and Ho (1996) found that replication proceeds on the order of 10.3 x 
10
9 
virions/day. Richman et al. (2004) demonstrated that an average of one mutation during 
each replication of each genome occurs. Mathematical models of HIV replicative error rates 
suggest that each day, every possible mutation—including drug resistance mutations—can 
occur at least once, and many may occur several times (Coffin, 1995; Perelson, et al., 1996). 
It is believed that retroviruses gain survival advantages from this high rate of error, enabling 
the frequent appearance of drug-resistance mutations, as well as a rapid rate of replication to 
create large numbers of viral particles (Mansky, 1998; Richman, et al., 2004). 
Immunological Events in HIV Infection 
Early infection.  The development of HIV infection begins with inoculation across 
broken skin or upon mucosa, usually rectal or vaginal in humans. Here tissue- or mucosa-
resident dendritic cells (DCs) acquire contact with the virus and transport particles to nearby 
lymphoid tissue, chiefly nodal tissue, where T-cell infection is thought to take place in DC/T-
cell complexes that are a normal part of the immune response. Evidence suggests that the 
DCs are not actively infected, although such cells do express low levels of CD4. It is believed 
that the proximity of the T-cells to active virus on the surfaces of DCs leads to the initial 
introduction of HIV into host cells for virus production (Dybul, Connors, & Fauci, 2005).  
 At this stage, serum viral burden may reach 10
7
 virions/mL and may cause acute 
retrovirus syndrome, a constellation of symptoms resembling influenza or mononucleosis, as 
nonspecific innate mechanisms and cytokines such as interferons are secreted by an activated 
immune system (Perelson, et al., 1996; Perlmutter, Glaser, & Oyugi, 1999; Streicher, et al., 
2000). The first antibodies to HIV appear within two weeks in some individuals, but may not 
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be detectable by typical commercial antibody assays until six weeks into infection. Early 
stage neutralizing antibodies exert no control on the rise of viral burden, with stronger 
humoral responses, supported by antibody-bound complement, and activated cytotoxic 
lymphocytes (CTL, CD8+lymphocytes) developing in 10-21 days to begin to bring the 
infection under control. The rise of this later, complement-binding antibody does seem to 
control viral spread (Pantaleo & Fauci, 1996).  
Chronic Infection. As serum viral burden decreases in response to the now-
invigorated and specific CTL response, two sources of persisting HIV are believed to be 
responsible for latent reservoirs of infection: proviral DNA woven into resting T-helper cells 
and follicular dendritic cells (FDCs) in peripheral lymphoid tissue (Pantaleo & Fauci, 1996). 
As was noted earlier, retroviruses copy their own genetic code into host target cell DNA 
strands. T-helper cells (THCs, CD4+ lymphocytes) are part of a pool of cells that assist 
thymic-dependent antibody responses by interacting with MHC-II/antigen complexes on B-
lymphocytes. Such helper cells also activate macrophages, assist CTL killing of virus-
infected cells by inducing proliferation of those cells, and induce cytokine production in 
response to infection. A pool of resting THCs may be ―naïve,‖ specific antigen-ready and 
unarmed, or they may instead be ―memory‖ cells, with matured antigen specificity and 
primed for rapid clonal expansion upon new contact with the ―memorized‖ antigen (Figure 
2.4).  
In either event, these lymphocytes are critical to initiating adaptive responses to new 
pathogens (naïve cells) and initiating rapid responses (with correspondingly lower energy 
costs) to previously-presented pathogen antigen (memory cells). The maintenance of the  
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  Figure 2.2 Idealized Model of T-cell Activity 
 
 
 
 
 
 
 
 
 
 
 
 
memory pool of THCs in particular sustains immune system competence and antigenic 
memory over decades (Janeway, et al., 2005). 
If it is the quality of the immune response and (Pantaleo et al., 1997) and the number 
of T-lymphocytes and other immune cells (Pantaleo & Fauci, 1996; Pantaleo, Graziosi, & 
Fauci, 1993) that together determine the level of sustained viremia in HIV patients, it is the 
persistence of the pool of resting CD4 cells, assisted by constant low-level stimulation from 
FDCs, that forestalls apoptosis, and maintains the infection itself. It has been shown that the 
deterioration of the CD4 lymphocyte pool may not even be due to direct killing by virus. 
Indeed HIV maintains T-cells as productive virus factories. Rather it may be immune 
activation (Sousa, Carneiro, Meier-Schellersheim, Grossman, & Victorino, 2002) and robust 
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CTL that depletes the host’s immunity and eventually leads to clinical symptoms (Borrow, 
Lewicki, Hahn, Shaw, & Oldstone, 1994; McMichael & Rowland-Jones, 2001). The clinical 
events that do result from diminution of the CD4+ lymphocyte pool is discussed further 
below. 
Late clinical events. Whatever the ultimate cause of the depletion of THCs, over a 
period of 18 months to 10 years, most untreated persons will develop some evidence of 
clinical disease (Mellors et al., 1997). There is ample evidence to suggest that genetic, 
immunologic, and possibly viral causes exist for both rapid, early disease, and non-
progression to clinical AIDS (Berger, et al., 1999; Cao, Qin, Zhang, Safrit, & Ho, 1995; 
Graziosi, et al., 1993; Haynes, Pantaleo, & Fauci, 1996; Pantaleo, et al., 1993; Wei et al., 
1995). Although it has been suggested that clinical progression in HIV disease may be a 
result of immune activation or immune dysregulation, opportunistic infection remains a 
significant cause of morbidity and mortality. Major primary causes of death worldwide from 
HIV include tuberculosis and Streptococcal pneumonia. Other causes are cervical neoplasia, 
lymphoma, and other cancers, especially those associated with certain viral infections, such 
as Kaposi’s sarcoma (associated with herpes simplex 8 infection) (Roizman, 1995). Thus, 
whatever factors cause sickness in HIV-infected patients pharmacologic suppression of virus 
remains the mainstay of treatment. This fact provides the impetus for this proposed study: If 
drug therapy matters, and if adherence matters, then means to maintain that adherence matter 
to nurses who treat HIV/AIDS patients.  
Antiretroviral Therapy and its Implications: The Bases for ART Today 
Zidovudine (ZDV) is a thymidine analogue that was found to be efficacious in the 
inhibition of the integration phase, though its blocking of reverse transcriptase at the coding 
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target (Furman et al., 1986; Parks et al., 1988; Shiau, Schinazi, Chen, & Prusoff, 1980; 
Uherova, Schmidtmayerova, & Mayer, 1991). Ultimately, single-agent therapy did not reduce 
significantly longer term mortality in AIDS patients, and there was evidence that the virus 
was becoming resistant to ZDV and that toxicity limited treatment tolerance (Rachlis, 1990). 
Zidovudine did not significantly alter the course of the disease (Volberding et al., 1994), and 
single class regimens of several nucleoside analogues were  not any more successful 
(HIV_Trialists_Collaborative_Group, 1999), and could be antagonistic (Havlir et al., 2000). 
In the mid-1990s multi-drug therapy studies in parallel with the development of 
polymerase chain reaction (PCR) techniques that allowed direct measurement of virus in 
serum, led to the conclusion that multiclass ART could hold the key to more durable 
effective treatment (Collier, Coombs, Schoenfeld, Bassett, Baruch, et al., 1996; Collier, 
Coombs, Schoenfeld, Bassett, Timpone, et al., 1996; Danner et al., 1995; Eron et al., 1995). 
A multi-center cohort study by Mellors, et al. (1997), showed that prognosis varied 
proportionally to viral load and inversely with CD4 counts. This seemed to suggest that 
durable, constant suppression of virus could forestall immune decline from HIV infection. 
These studies seemed to suggest that saving HIV patients could be accomplished through 
attacking the life cycle at two or more points (Gulick et al., 1998; Gulick et al., 1997; 
Hammer et al., 1996; Hammer et al., 1997; Palella et al., 1997). Recent data demonstrate that 
potency alone may not be enough to control HIV, as ―triple nucleoside‖ regimens proved 
inadequate to provide long term control for patients with serum viral loads above 100,000 
copies/mL (Gulick et al., 2004). Inhibitors of the RT enzyme itself (as opposed to inhibition 
of its substrates, e.g., thymidine), inhibitors of protease, and more recently, inhibitors of 
fusion have been combined with nucleoside RT inhibitors, such as ZDV, to create effective 
 20 
 
multiclass ART (Palella, et al., 1997; Panel_on_Antiretroviral_Guidelines_for_Adult_and_ 
Adolescents, 2006; Sepkowitz, 2001). 
Antiretroviral Resistance and Adherence 
The dynamics of HIV, the consequence of unchecked infection, and the effectiveness 
of multiclass ART were explained in previous sections. To summarize: HIV ―writes itself‖ 
into the genetic code of host cells, chiefly CD4+ lymphocytes and macrophages. Viral 
elimination may not be possible: resting memory T-cells may harbor proviral DNA for 
decades, sequestered from the action of available drug therapy (Finzi et al., 1999). 
Replication proceeds with many errors, yielding inactive virus, but also yielding some 
adaptive mutations. Thus, the cornerstone of ART now is the creation of regimens that 
effectively shut down viral replication. If there is no replication, there can be little to no 
opportunity for the creation of drug resistance mutations (Patel & Patel, 2006).  
Viral replication commences relatively soon after serum drug levels fall below their 
inhibitory concentrations (Blaise, Clevenbergh, Vaira, Moutschen, & Dellamonica, 2002; 
Tobin et al., 2005). The goal of ART is to maintain constant, therapeutic drug levels. Missing 
doses may lead to drug levels falling below those levels. There are many reasons for non-
adherence, including patient preference or competing life goals, various behavioral or 
psychological impediments such as substances abuse or low self-esteem, and socio-economic 
problems to include changing residence jurisdiction (e.g.,  for patients on public assistance), 
and so forth (Benedetto, 2003; Chesney, 2000; Marhefka, 2002; Ramirez & Cote, 2003). The 
present study was concerned with non-adherence related to unpleasant side effect symptoms, 
whether they are from the actions of the drugs or from psychosomatic effects, such as nocebo 
or context effects. 
 21 
 
 Variations in adherence have been characterized based on dosing frequency alone 
(Mannheimer, Friedland, Matts, Child, & Chesney, 2002) and dosing frequency versus dose 
timing (Ferguson et al., 2005), with the former having been better studied. An ideal 
adherence level of >90% of doses taken is associated with durable viral suppression (Robert 
Gross et al., 2006; Lowe, Prins, & Lange, 2004; Press, Tyndall, Wood, Hogg, & Montaner, 
2002). The high rate of replicative error combined with loss of viral suppression leads to the 
emergence of viral resistance (De Olalla et al., 2002; Rouzine & Coffin, 2005).  
 Thus, the goal of ART is to suppress virus and spare the immune system both CD4 T 
cell depletion and excessive chronic activation. Clinical deterioration has been shown to 
correlate well with levels of CD4+ lymphocytes (Fahey, et al., 1990). Suppression of virus 
leads to a restoration of certain immune cell subsets, and has been shown to thus lead to 
immune reconstitution and clinical improvement (Hung & Chang, 2004). If patients cannot 
adhere because of side effects, or suffer too long from feeling ill on ART, adherence can 
suffer, and this can lead to loss of suppression outright (when medications are halted) and/or 
drug resistance (when medications are taken correctly less than 90% of the time) (Press, et 
al., 2002; Rouzine & Coffin, 2005). 
Summary 
 Infection with HIV is persistent, and at present permanent, due to the unique way that 
retroviruses become part of the host cell genome. Infection is highly dynamic and results in 
significant immune system activation. Infection also targets specific human immune cell 
types that lead to weakening of immunity, and opportunistic infection is a late and often fatal 
result. Persistence of the virus owes to persistence of very specific THC subsets that are long-
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lived. Although virus may be suppressed for years, small numbers of resting THCs are 
enough to seed a full-scale reinfection if drug pressure is removed. 
 The dynamics of HIV result in many mutations, and drug resistance mutations are a 
daily occurrence, but competition with wild-type virus limits its persistence in the host. Drug 
pressure suppresses viral replication and also limits the emergence of drug resistance. 
Intermittent use of ART or the use of incomplete regimens lead to incomplete suppression, 
and drug resistant variants emerge. These variants lead to viremia despite therapy, and the 
clinical consequences of unchecked HIV infection can resume. The effectiveness of entire 
classes of antiretroviral drugs can be lost. 
 For these reasons, ART is currently considered a lifelong therapeutic enterprise. 
Interruptions are not usually catastrophic, but can only be short-lived in most patients. 
Reasons for interruption include drug toxicity. Otherwise, patients must remain on ART 
continuously. Minimizing side effect symptoms assists the goal of adherence, and continuous 
adherence is, for now, the only effective long term treatment strategy in HIV disease. 
Educating Patients for Adherence to Antiretroviral Therapy 
From early in the era of ART it was observed that failure to adhere to medications 
properly can lead to drug resistance (Bangsberg, 2006; Bangsberg et al., 2000; Blaise, et al., 
2002; Tobin, et al., 2005),  that this can lead to poor clinical outcomes (De Olalla, et al., 
2002; Press, et al., 2002; Richman, 1994), and thus requires diligent efforts toward improving 
patient adherence to the regimens as prescribed (Esch & Frank, 2001). ―Adherence 
education‖ or ―adherence training‖ are terms that have arisen in the clinical vernacular of 
HIV specialist clinicians whose patients often expect to actively participate in their care 
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choices, an outcome of the activist politics surrounding the HIV epidemic. This raises the 
question: In HIV treatment, what is adherence education? 
 Teaching patients how to utilize a prescribed regimen is probably one of the oldest 
interventions in human history, and Hippocrates referred to patients who did not take their 
medications for various reasons (Vermeire, et al., 2001). It is beyond the scope of this project 
to review everything known about teaching patients how to use their medications. However, 
establishing that regimens are complex, that failure to take the regimens properly can have 
serious consequences, and that therefore adherence has special significance in ART calls for 
a discussion of adherence as it applies to ART.  It is also important to note that reviews of 
―patient compliance‖ tend to devolve to a few issues. Patients choose to adhere to medical 
regimens when the expected gain exceeds the perceived losses—in time and inconvenience, 
in suffering due to side effects, in their sense of social stigma (especially pertinent in disease 
like HIV/AIDS) (C. Golin, Isasi, Bontempi, & Eng, 2002; Wilson, Hutchinson, & Holzemer, 
2002). Also important is that patients believe that their concerns about treatment have been 
heard and have formed part of the plan (Dunbar, 1980; Lieberman, 1996). Yet as Chesney 
(2003) notes, substance abuse, domestic violence, transience of habitation, loss of insurance 
and other issues have significance as well. These issues could be subsumed under the rubric 
―readiness to therapy.‖ But readiness to therapy is more complex than that. There is also the 
notion of a diffuse, highly personal sense of ―readiness‖ for any medical undertaking 
(Bartlett, 2002) that has become well-recognized in HIV/AIDS care. Putting this individual 
and personal sense of readiness together with actual social impediments to therapy, gives a 
more complete definition to ―patient readiness.‖  
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Lucas, Chaisson, and Moore (1999) report that  availability of social support systems, 
patients’ ability to fit medication dosing into their routines, and the sense that they can dose 
without stigma (take HIV medications in front of others) contribute to adherence. 
Furthermore, when patients keep clinic appointments, and when they understand that missing 
doses or taking doses late leads to viral resistance, adherence predictably improves. The 
Panel on Antiretroviral Guidelines for Adults and Adolescents (PAGAA) (2006) advises that 
a ―trusting relationship‖ among patient and health care team is essential (p. 2), and that 
continual communication between patient and team contribute to readiness to therapy as well 
as adherence. Active substance abuse (Sherer, 1998), untreated mental illness (Kemppainen 
et al., 2004; Uldall, Palmer, Whetten, & Mellins, 2004), and current living status may 
interfere with readiness and need to be considered as part of adherence readiness assessment 
and education planning (PAGAA, 2006). Next, a suggested standard of care for adherence 
training is considered. 
In a study by Murphy, Lu, Martin, Hoffman, and Marelich (2002) several features of 
what many clinicians would consider to be a ―good‖ adherence training approach were  
employed in a pilot among 33 patients on ART. Those features include individualized 
training sessions to discuss readiness for ART, incorporation of the regimen into the patients’ 
lifestyles, and also strategies not commonly employed in clinics such as group sessions to 
explain treatment rationales, how adherence influences the development of drug resistance, 
and so forth. In this study, ―standard care‖ was less formal and was described as ―the regular 
care provided by the clinic as its normal policy‖ (Murphy et al. p. 60). The authors go on to 
state that this consisted of  
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…the usual inquiries at regular appointments as to difficulty with adherence; those 
reporting problems received a single 30-minute consultation, had their medication 
schedule written down for them, and received no further intervention. (Murphy et al., 
2002, p. 60) 
 A study by Safren, et al. (2001) highlights the difficulty in coming to a common 
definition of ―standard of care‖ in preparing a patient to take a complicated regimen of fairly 
toxic medication, and in which non-adherence may have significant health consequences over 
the long term. In their study of the use of two psychobehavioral strategies to enhance 
adherence, the control group or patients in the ―self-monitoring condition‖ (p. 1155) the 
authors do not even describe what initial education patients received about dosing, what to do 
on ―sick days,‖ and other potential conditions noted above in the material from University of 
California San Francisco and AIDS Education and Training Center. In the ―Life Steps 
[intervention] condition‖ the group received interventions that included ―eleven 
informational, problem-solving, and cognitive-behavioral steps for improving adherence…‖ 
which include ―obtaining medications…formulation of a daily medication schedule…‖ and 
―cues for pill-taking‖ (p. 1156). Also included are strategies such as guided imagery (GI). 
The problem is that many of their intervention strategies are included in current educational 
interventions undertaken by clinicians, nurses, and pharmacists, depending on who is 
assigned to the task in any given clinic. In the researcher’s experience it is common for 
several such points to be covered in varying depths by several such agents in a given patient 
visit—especially if a new regimen is being prescribed, or there has been a change in one or 
more agents in the regimen. Since the beginning of combination ART for HIV, clinicians and 
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others involved in care have been teaching patients about dosing times and other items in the 
list of the intervention by Safren et al. 
 That clinicians and other staffers may not always address the items noted in the lists 
above in the same way, style, depth, or detail was the subject of a study by Golin, Smith, and 
Reif  (2004). They sought information about the adherence training habits of a sample of 589 
physicians in North Carolina. With a response rate of 63%, 369 respondents reported 
spending an average of 13 minutes counseling patients who were starting a new or changed 
regimen, and covered an average of seven of 16 ―counseling behaviors‖ on a checklist 
developed by the researchers, adapted from items from the Adherence and Efficacy of 
Protease Inhibitor Therapy Study (ADEPT) provider adherence behavior scale, The United 
States Pharmacopeia (USP) Medication Counseling Behavior Guidelines, and U.S. 
government guidelines for Medicare. The authors concluded that physicians treating 
HIV/AIDS patients need additional training in adherence as well as more time to deliver the 
messages that support adherence. This researcher’s question would be: Given the immense 
amount of information available in every form: oral presentations, journal articles, websites, 
and even colleagues in nursing and pharmacy, is it really a problem of ―lack of training‖?  
Conclusion 
 Adherence education is an important part of how patients acquire facility with their 
medical regimens. Several authorities propose very similar schemes to assure that patients 
understand the goals of drug therapy, special features of the regimen (e.g., timing with 
meals), and how to manage side effects, as well as the consequences of nonadherence. 
Evidence suggests that adherence education in the clinic is variable. On the one hand, it is 
necessary to assess patients’ knowledge and capabilities and to adapt education appropriately. 
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On the other hand variability and missed opportunities are common. Reconciling these two 
issues for this study is discussed in the chapter on methodology. 
Cognitive-Behavioral Therapy for Symptom Management 
 Much of the research into the management of symptoms using CBT involves 
cancer—either the symptoms of the disease itself, or symptoms that arise from treatment. 
Such experience forms a basis for the proposed study. 
It was during the time of burgeoning research into the so-called ―mind-body 
connection‖ during the 1970s, that pharmacological and radiological interventions for cancer 
were also gaining greater success against the disease. Such therapies came with serious side 
effects, ranging from local and systemic pain, to nausea/vomiting, debilitating fatigue, and 
even anxiety related to such adverse effects, a condition of their use that still obtains today 
(Golden, 1975; Sausville & Longo, 2001; Schnell, 2003). This resulted in a number of 
investigators looking into whether techniques effective in achieving autonomic control could 
also be effective in helping cancer patients achieve greater comfort during treatment cycles. 
Indirectly, this might improve adherence or willingness to continue chemotherapy. The next 
section reviews the literature on the management of symptoms, with emphasis on symptoms 
in cancer and HIV. 
Nausea and Vomiting. One of the thornier problems in antineoplastic therapy is that 
of control of nausea and vomiting (Grunberg, Hansen, Deuson, & Mavros, 2002). Most 
patients find these symptoms highly aversive, and their control is considered one of the keys 
to successfully engaging patients in continuing chemotherapy. Promethazine, 
metoclopramide, corticosteroids, and a host of other antiemetics have been used to relieve 
nausea (Morrow, Roscoe, Hickok, Andrews, & Matteson, 2002; Schnell, 2003). At the time 
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of this writing, the 5-hydroxytryptamine-3 receptor (5-HT3) antagonists are demonstrated to 
be the most effective pharmacologic means of controlling nausea and vomiting (NCCN, 
2005). It is understood that serotonin, released from enterochomaffin cells in the small 
intestine, activates the chemoreceptor trigger zone (CTZ) during some antineoplastic therapy 
(Schnell, 2003), but what is not understood is why agents such as cisplatin, 
cyclophosphamide, and doxorubicin have such a high emetogenic potential in this regard. 
Nevertheless, such agents can be reliably expected to produce nausea and vomiting in most 
patients (60-90%) (Schnell).  
 Two conditions related to nausea in antineoplastic therapy cause patients to continue 
to suffer from the symptom. The first is that although antiemetic therapy has become more 
effective (Gralla et al., 1999; Grunberg, et al., 2002), not all patients respond to it with 
complete or significant reduction in discomfort (Gralla, et al., 1999). Second, if control is 
lacking, and depending on the sensitivity of any given patient to distress related to nausea, 
some patients become conditioned to expect the nausea and vomiting, and this may lead to 
ANV (Burish & Carey, 1986; Zachariae et al., 2007). Cancer patients may grow ill on the 
way to the clinic, or the day prior to a treatment round, or even in situations that remind them 
of chemotherapy (such as a dentist’s office) (Morrow et al., 1992; Morrow, Roscoe, Kirshner, 
Hynes, & Rosenbluth, 1998; Schnell, 2003). Zachariae et al.(2007), using several scales of 
sensitivity and reactivity (Tellegen Absorption Scale, the Somato-Sensory Amplification 
Scale, and the Autonomic Perception Questionnaire) found that ―openness‖ to absorbing new 
situations, and suggestibility tended to increase ANV. A review by Morrow, Roscoe, Hickok, 
and Matteson (2002) supports the view that while newer antiemetics are more effective, 
nausea and vomiting—anticipatory and otherwise—remain a clinical problem in 
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antineoplastic therapy. Both medical and behavioral techniques are required to fully address 
the biological and behavioral reasons for the symptoms.  
Behavioral Interventions in Nausea and Vomiting in Antineoplastic Therapy 
Several studies have shown that relaxation training that helps patients moderate their 
anxiety may significantly reduce conditioned responses that lead to ANV. Dempster, Balson, 
and Whalen (1976) describe a case utilizing hypnotherapy as a means to reduce anticipatory 
nausea and anxiety in a female undergoing antineoplastic therapy with nitrogen mustard for 
Hodgkin’s disease. She responded well to the intervention and was able to continue with her 
therapy. She also expressed more ―hopeful feelings‖ (p. 7) about being able to live with her 
disease and the treatment.  
Burish and Lyles (Burish & Lyles, 1979) found that relaxation training allowed a 
woman to successfully tolerate chemotherapy for lymphoma. Consequently, they followed 
this with a small trial of 14 participants  (cancer type not stated) (Burish & Lyles, 1981) and 
demonstrated significant (p<.05) improvements in mood (anxiety, anger, and depression as 
measured by the Multiple Affect Adjective Checklist) and post-treatment nausea (verbal 
Likert scale developed by the authors) as well as lower physical arousal (pulse rate; 
differences in blood pressure were non-significant). Similar studies with similar designs and 
dependent measures confirmed significant trends toward lessened nausea, improvements in 
mood, and decreased arousal (Burish, Carey, Krozely, & Greco, 1987; Burish & Jenkins, 
1992; Burish, Snyder, & Jenkins, 1991; Burish & Tope, 1992; Carey & Burish, 1988). 
Morrow et al. (1992) were able to show that techniques such as progressive muscle 
relaxation, directed at reducing nausea in cancer patients undergoing antineoplastic therapy, 
were generally safe and effective even when delivered by nurses or oncologists. A 
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psychologist or therapist did not have to be present to deliver such interventions. The authors 
note that medical personnel should not engage patients in psychotherapy or other 
interventions that might require the spectrum of skills that would require special training in 
psychology. 
One negative study by Syrjala, Cummings, and Donaldson (1992) found that hypnosis 
did not significantly reduce symptoms of nausea (although it did reduce oral pain) in the 
treatment arm of a trial of 67 bone marrow transplant patients. Distraction as a technique, was 
tested against relaxation in 60 patients assigned to one of six groups in a 2 x 3 factorial 
design, based on their pre-intervention level of anxiety, and to either intervention or the 
control condition (Vasterling, Jenkins, Tope, & Burish, 1993). There was no difference 
between the interventions; both significantly reduced nausea and physiologic arousal (blood 
pressure). 
Over the last several decades, it has been shown that behavioral management is an 
important adjunct to medical therapies directed at relieving nausea in antineoplastic therapy 
(Redd, 1994). Later reviews that attempted to determine the most effective behavioral 
approaches have shown that techniques that reduce physiological arousal and induce trance 
or semi-trance states such as hypnosis, and relaxation, and cognitive techniques such as 
guided imagery exert the greatest effects in symptom reduction (Mundy, DuHamel, & 
Montgomery, 2003; Redd, Montgomery, & DuHamel, 2001).   
Behavioral Interventions Used to reduce Pain: Acute pain may be managed 
through cognitive/behavioral means (Chen, Joseph, & Zeltzer, 2000; Kuttner, 1989; Logan, 
Baron, & Kohout, 1995; Rusy & Weisman, 2000; Tan & Poser, 1982). Chronic pain presents 
more challenge, and chronic pain has drawn significantly more attention in terms of CBT 
 31 
 
interventions (Adams, Poole, & Richardson, 2006; Eccleston, 2001; Frischenschlager & 
Pucher, 2002; Morley, Eccleston, & Williams, 1999; Nielson & Weir, 2001; Turk, 2003) 
Perhaps this owes to the fact that analgesics are often effective for short-term pain, and acute 
pain often has a definable proximate cause (e.g., appendicitis, sprain, side effects from 
drugs).   
 By the mid-1980s a small number of studies had tested the effectiveness of CBT in 
the management of cancer pain. Caudell’s (1996) review mixed studies of pain, ANV, and 
anxiety, as well as great variety of CBT interventions (e.g., distractions, relaxation, etc.)—as 
well as non-CBT interventions such as Therapeutic Touch—and concluded that such 
therapies could easily be included in nursing practice, but spoke with less certainly to 
whether such therapies are effective. It can be argued that Caudell’s review, while admirable 
for its humanism, did not apply adequate inclusion criteria to her review. 
 Morley, et al. (1999) contributed a meta-analysis of chronic pain management in 
patients other than those with cancer. Twenty-five papers met inclusion criteria, and 
diagnoses included musculoskeletal and neuropathic pain of various types but excluded 
headache. They concluded that significant effect sizes occurred for all intervention groups, 
when controls were applied for variations in measurement reliability. In another meta-
analysis (McCracken & Turk, 2002) of pain other than that caused by cancer, patients’ sense 
of control and willingness to participate in their pain management was significantly 
correlated with effect sizes.  
A panel at the U.S. National Institutes of Health (Anonymous, 1996) determined that 
psycho-behavioral interventions are a useful adjunct in chronic pain management. The 
strongest evidence for efficacy was for hypnosis and relaxation techniques alone, and 
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moderate effects for cognitive behavioral therapy (which may or may not include those 
specific behavioral techniques, as ―cognitive behavioral therapy‖ encompasses a large subset 
of behavioral supports). 
Devine and Westlake (2003) reported on a meta-analysis of 25 studies of adults with 
cancer pain and the use of CBT. Methodological quality varied considerably; several trials 
did not employ random assignment. When the analysis was limited to better quality studies, a 
statistically significant improvement in pain control remained evident, with the most 
effectiveness seen in trials employing relaxation techniques. In a review (Semple, Sullivan, 
Dunwoody, & Kernohan, 2004) of the use of psychological interventions as adjunctive pain 
management in head and neck cancer, studies tended to support the effectiveness of CBT 
over other psychological interventions. Tatrow and Montgomery (2006), in a meta-analysis 
of  20 studies of CBT to reduce distress and pain in breast cancer patients found that CBT 
effect sizes were .49 reduction of pain regardless of whether or not metastasis had occurred. 
Effect sizes for reducing distress were more modest, averaging .31. 
 As in the case of nausea and antineoplastic therapy, the perceptions of pain were 
reduced with CBT, with particular effectiveness of interventions that employed relaxation or 
hypnotic-type therapies (and guided imagery may be said to obtain this categorization, since 
it is typically employed after induction of relaxation by other means). Note that this review 
does not distinguish between pain caused by antineoplastic therapy and pain caused by cancer 
itself. The meta-analyses above focused on studies of pain as experienced by the cancer 
patient regardless of cause, the exceptions being the reviews by Redd et al. (2001) and 
Mundy et al. (2003). 
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Note on the Pain and the Side Effects of ART.  It is a generally-accepted axiom of 
nursing that pain is whatever the patient says it is, and an assumption follows that pain may 
not have a definable, relievable pathophysiological cause.  It is also axiomatic such an 
assumption arises from exclusion of treatable causes. In clinical experience HIV/AIDS 
patients have complained of ―pain‖ related to ART, but not always pain that could be related 
to known side effects or toxicities that are ordinarily accompanied by pain. Conversely, 
pain—or any symptom—may arise from a problem with a given medication. For example, 
zidovudine may cause lactic acidosis with accompanying abdominal pain (GlaxoSmithKline, 
2005). Johnson, Stallworth, and Neilands (2003) examined the causal attributions of 
symptoms held by HIV/AIDS patients: disease, medicine, or neither (i.e., a non-HIV, non-
ART cause, such as reflux disease, heart disease, etc.) They found that such patients 
generally assigned certain types of symptoms, e.g., adenitis, to the disease. This agrees with 
what most patients are told about the symptoms of HIV disease. Side effect symptoms tended 
to be those that could be temporally related to the start of ART or related to dosing times. 
Their study found that in either case, side effect or disease symptom, correct attribution is not 
always certain. Patients may mislabel symptoms as side effects and vice-versa, creating 
problems for clinical interpretation, especially if information is omitted by the patient 
because they believe a symptom unrelated to medication. More to the point with respect to 
the current review, is that there is no solid line between symptoms attributable to disease 
states or ART side effects.  
In general, CBT is effective for chronic pain, and evidence supports the use of CBT in 
cancer/cancer treatment pain. In particular, effectiveness was seen with the inclusion of 
hypnotic and relaxation-based interventions in this population. 
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Behavioral Interventions in Fatigue. A search for studies that utilized a cognitive, 
behavioral or dual therapeutic intervention (CBT) to reduce fatigue in cancer patients, 
returned three studies. Levesque, Savard, Simard, Gauthier, and  Ivers (2004) employed 
cognitive therapy as an intervention for depression in cancer patients in a single group 
pretest/posttest design. Depression improved, as well as associated symptoms such as 
anhedonia and fatigue.  Given et al. (2004) conducted a randomized clinical trial using CBT 
as the experimental intervention. Fifteen symptoms were measured by severity on 11-point 
rating scales (0-10); the scores were then summed to create a scale from 0-150 global score. 
The intervention included cognitive approaches (e.g., skills development, self-persuasion, 
problem solving) and behavioral methods, although these are not specifically reported, as 
they were tailored to each patient’s needs. Global symptom scores improved at 10 and 20 
weeks, but the report did not break down the analysis by individual symptom. A very similar 
study a year later (Sherwood et al., 2005) also demonstrated improvements in symptom 
scores at 10 and 20 weeks, and again the symptoms were not individually analyzed. A single 
randomized trial that addressed CBT and fatigue in female HIV patients (Lechner et al., 
2003) utilized a cognitive-behavioral stress management/expressive-supportive therapy 
intervention to improve quality of life (QOL), operationalized with the Medical Outcomes 
Study 30-item (MOS-30) scale for HIV. The intervention group demonstrated a statistically 
significant improvement in total MOS-30 scores by analysis of variance (p<.05) and overall 
health distress and health perceptions (p<.001), but fatigue, and single-item scores did not 
change significantly. 
Fatigue is a common symptom in HIV patients, and it stems from several causes, 
some treatable with medication, hygiene, or regimen changes. Other causes are less certain. 
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Few studies exist—in oncology or HIV care—that examine the effectiveness of CBT in 
treating this symptom. 
 Anxiety. Anxiety presents a special case. Not only is anxiety itself uncomfortable for 
the patient, but it tends to potentiate other symptoms. Sternbach (1975) noted that anxiety 
aggravates pain and suggested the exploration of biofeedback as one means of reducing the 
anxiety that is both associated with pain, and worsened by it. In the discussion of Burish and 
Lyles’ (1979) 30-year-old cancer patient with side effect symptoms, her negative affect 
decreased with CBT and this was associated with concordant decreases in other symptoms 
such as pain and nausea. In a trial by Lerman, et al. (1990) coping styles that featured 
information gathering and ―monitoring‖ were associated with heightened anxiety. The higher 
levels of anxiety correlated with increases in nausea and other physical side effect symptoms 
in those participants. Coping styles that employed distraction were associated with less 
anxiety and also blunted physical side effects. Kalichman (1995, pp. 223-224), argues that 
shifting HIV patients’ locus of control inward helps them to assert power in their own 
cognitive domain. Since the cortex—thought—is the final common pathway of symptom 
experience, it seems logical that any therapy that reinforces the patients’ power over thoughts 
could be expected to blunt or otherwise alter such symptoms as they are experienced.  
Starcevic (2006) reviewed conceptual and treatment issues in anxiety and reports that 
CBT is effective at treating the disorder, not only in clinical trials but in routine clinical 
settings. In their review of CBT used to treat ―ordinary‖ psychiatric problems such as 
depression and anxiety, Hollon, Stewart, and Strunk (2006) found that medications were 
largely palliative, while CBT interventions seemed to show a trend toward more enduring 
effects. The effects could not be accounted for by methodological issues alone. However, 
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they do not conclude whether this trend to improvement is the result of ameliorations of 
factors that led to illness, or to the mobilization of patients’ own psychological skills. 
Two meta-analyses were conducted by Sheard and Maguire (1999), one for 
depression (20 trials) and one for anxiety (19 trials), in cancer patients treated with 
psychological interventions. Most of the studies used CBT or some variant of CBT. 
Psychological interventions had a negligible clinical effect on depression, and a moderate 
effect on anxiety (mean effect size .36), with the most robust effects seen in four trials that 
focused on prevention (.94) of anxiety. In summary, CBT is effective in reducing anxiety, 
although it is not certain how much improvement represents individuals’ adaptations over 
time, and the role of medications and other medical changes. 
Antiretroviral Therapy and CBT 
Side Effect Symptoms and Adherence to ART. Several studies looked at the impact 
of side effects on patients taking ART. Ammassari et al. (2001) undertook a multicenter, 
descriptive study that examined correlates of adherence. Patient’s level of side effects on a 
16-item symptom questionnaire significantly inversely correlated with level of adherence, 
with greater number and intensity of side effects associated with lower levels of adherence. 
Brook et al. (2001) examined reasons patients chose to skip doses and/or discontinue 
otherwise successful regimens in a twelve-center study in England. Lack of motivation was 
found to have the largest impact leading to poor adherence, but side effects were a 
statistically significant factor in their descriptive study.  
Regimen selection has been proposed as a means of improving adherence, based in 
part on a study by Miller, Huffman, Weidmer, and Hays (2002), which  found that anticipated 
side effects have an impact on patient preferences for various regimens.  The authors argue 
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that factoring anticipated side effects and patients’ individual tolerance for various such 
effects could improve adherence, and improve clinical endpoints. A grounded theory study 
by Wilson, Hutchinson, and Holzemer (2002) proposed a theory of nonadherence that 
encompassed self-identity, illness ideology, concurrent treatment regimens, the meaning of 
time, medication burden and side effects, and lifestyle, that coalesce to produce a state of 
mind that shapes adherence choices on a dose-by-dose basis. Some of their suggestions for 
intervention include education about side effect management, with reframing among them.  
No studies have specifically tested this theory. Based on the foregoing work, subsequent 
studies have explored the educational and the cognitive/behavioral approach, respectively. In 
a prospective pilot study, medication adherence improved with the use of weekly medication 
counseling sessions, focused on various management issues, and including a pill organizer 
(McPherson-Baker et al., 2000). Similar results were found in a prospective study of 997 
patients (Weiss et al., 2003). Knowledge about ART was significantly associated with 
adherence. Using logistic regression analysis to analyze the number of correct questions out 
of five, fewer than four correct answers increased the odds of self-reported nonadherence 
(OR = 1.72 for 2-3 correct, p<.01; OR = 2.92 for 0-1 correct, p<.05).  Gellaitry et al. (2005) 
studied patient satisfaction with medication education in 115 participants. Using a validated 
questionnaire, the authors found that patients who reported less satisfaction with the 
information they received about ART to be more likely to decline therapy (p<.05).  Declining 
ART was significantly associated with concern about potential adverse effects of therapy 
(p<.001).The authors conclude that individualizing education may improve acceptance of 
ART. The most significant feature of these studies is that the dependent variables were all 
based on patient adherence, with clinical endpoints (CD4 and HIV RNA) not measured—
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these were assumed to improve because of adherence, as noted in earlier sections of this 
paper. 
A review by Haddad et al. (2005) of the available trials of educational interventions to 
improve adherence, found that only one trial included the a comparison group and a measure 
of adherence. Their conclusion was that only a pharmacist-led educational intervention 
improved adherence significantly. Improved adherence in that study was associated with viral 
loads below the limit of detection, regardless of participation in the intervention. In other 
words, participating in the intervention did not statistically predict undetectable viral load, 
only improved adherence, regardless of how patients got there. The authors also noted that 
more trials looking at clinical endpoints should be considered for study. 
The Use of CBT in ART. The review sought to answer two questions. The first 
question asked to what extent have CBT approaches been used to either mitigate symptom 
side effects in ART, or to improve adherence (whether or not symptom control was tested)? 
The second question asked if such techniques have been used, which techniques were most 
effective in HIV/AIDS and ART? 
During the period February 2004 to December 2006 a series of searches were 
conducted in Pubmed/MEDLINE, CINAHL, and PsyLIT databases. Search terms that would 
encompass cognitive-behavioral therapy (e.g., ―cognitive therapy,‖ ―behavioral therapy,‖ 
―relaxation‖) were joined with terms to encompass ART/therapeutics, medication 
adherence/compliance, and HIV and/or AIDS.  In the most recent search, 18 studies were 
cataloged. Six of these studies met the criteria for inclusion: An individualized cognitive, 
behavioral, or combination approach was the intervention in a clinical trial, pilot study with 
or without control, or case series. The intervention could affect any variable related to 
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adherence or symptom control (including mood, or cognitive processes that could help 
improve mood). The six studies are summarized below. 
Using a pre-test/post-test design among Taiwanese HIV patients, Chiou et al. (2004) 
found that fewer hospital visits occurred among HIV patients on ART when an educational 
intervention was used to teach management of side effects. This three-arm trial compared a 
control group, and two experimental groups, one which received a group therapy 
intervention, and the other which received individualized therapy. The control received 
―standard‖ teaching on medication use. Hospital visits decreased in both group and 
individualized interventions, but there was no statistical difference between the two groups. 
Although the clinical endpoints for HIV and adherence were not studied, the authors 
conclude that a reduction in hospital visits reduces burden on the health care system and 
gives HIV patients on ART the tools to manage side effects effectively. The study was 
included here based on the assumption that symptom control could serve as a reason a patient 
would visit the hospital (―visit‖ included visits to emergency wards, even if the patient was 
discharged the same day). 
The remaining four studies examined the impact of CBT. Two small studies (Ironson 
et al., 2001; Murphy, et al., 2002) examined the use of CBT to increase self-efficacy among 
HIV patients, as it affects adherence, clinical endpoints, and perceived distress. Murphy, et al. 
(2002) sought to test the hypothesis that enhanced self-efficacy—the ability to assert oneself 
with clinicians, ask questions, report problems, etc.—would lead to improvements in 
adherence, less distress, and greater life satisfaction. Twelve participants were randomized to 
receive standard medication education (SME) or SME and cognitive/behavioral interventions 
designed to enhance self-efficacy (e.g., coping strategies, engaging social support). 
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Reframing, relaxation, and distraction, were not among the CBT techniques used, and there 
were no CBT interventions devoted solely to management of side effects or distress related to 
side effects.  A statistically significant improvement in self-efficacy was found using the 
Antiretroviral Medication Adherence Coping Strategies Scale, which was used to measure 
patient-physician communication, social support, and acceptance of need for medication 
(p<.05). However, there was no significant difference between groups for adherence, 
measured by self-report (although the authors report a trend toward significance). This may 
result from the small number of participants (n = 33). 
Ironson et al. (2005) looked  at whether CBT might have an impact on self-efficacy 
and disease markers (CD4 and viral load). In a randomized, controlled clinical trial with 56 
women, the researchers tested the question: does self-efficacy improve clinical endpoints in 
HIV disease? Fifty-six women were randomized into intervention and control groups.  The 
intervention targeted general measures of self-efficacy, operationalized in a self-efficacy 
measurement tool developed by the authors. The actual intervention emphasized reframing 
thoughts about ART, developing assertive responses (e.g., asking questions when some 
technical aspect of ART wasn’t understood clearly), and relaxation techniques. Clinical 
endpoints improved in the intervention group; the results were statistically significant. 
Adherence was not measured.  However, the authors discuss that it is unclear as to how or 
why CD4 counts improved and viral load decreased: was it greater adherence or some as-yet-
under described effect of thought on the subjects’ immune systems? 
Two studies (Jones et al., 2003; Parsons, Rosof, Punzalan, & Di Maria, 2005)  
examined the how the choice of CBT strategy might change adherence.  Jones et al., in a 
study of 174 low-adhering women randomly assigned 82 women to a ten-session psycho-
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educational intervention, based on principles of cognitive therapy and stress management, 
that was designed to encourage the women to express their concerns, beliefs, and knowledge 
of ART, including its potential impact on their lives and the courses of their disease. The 
intervention was intended to improve coping, and was not designed to improve adherence, 
although it was hypothesized that adherence might improve. Denial-based coping did 
improve in the intervention group, and low-adhering women did increase their self-reported 
adherence by 30% (p<.01) Adherence in the control group did not improve. 
The study by Parsons et. al. (2005) focused on substance abuse as a main factor 
contributing to non-adherence. They sought to test a cognitive-behavioral intervention that 
would prevent relapse as well as preventing behaviors in which substance abuse would 
interfere with regular ART dosing. As in the study by Jones, et al. (2003) the intervention 
was based heavily on engaging cognitive processes, through the use of classical cognitive 
therapy and motivational interviewing. Eleven participants completed the full eight weeks of 
sessions with the therapists, and the remaining four completed between two and six sessions, 
with twelve participants available for the final three-month follow up evaluation. The authors 
report that the study was too small to show an effect. However, a non-significant trend 
toward improved adherence was evident.  
Two studies (Molassiotis et al., 2002; Molassiotis, Lopez-Nahas, Chung, & Lam, 
2003) sought to examine the impact of CBT on adherence. In a pilot study (Molassiotis, et 
al., 2002) of 46 Chinese patients that used a group CBT intervention there was a statistically 
significant improvement in both mood (Profile of Mood States) and quality of life (World 
Health Organization Quality of Life-BREF-HK Scale). Because it was a group intervention, 
it does not strictly meet the criteria for this review. It is included here because it formed the 
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basis for a second study by Molassiotis, Lopez-Nahas, Chung, & Lam (2003), 12 Chinese 
patients using individualized CBT, with most of the emphasis on cognitive strategies, 
especially education about medication use. This study also found statistically significant 
improvements in adherence (self report) and CD4 counts in the intervention group (t-test of 
means from AIDS Clinical Trial Group [ACTG] Adherence questionnaire, p<.05).  The 
authors conclude this is due to greater adherence to medications. The five studies that focused 
on individualized interventions are summarized in Table 2.1. 
Discussion: The use of CBT in improving symptom control during ART has not been 
studied. The existing literature suggests that CBT has been used to effectively improve 
adherence to ART. Most of the interventions emphasized the use of cognitive strategies: 
reframing maladaptive thinking about ART, improving coping skills, and confronting 
concerns and beliefs about ART. Two studies (Ironson, et al., 2001; Molassiotis, et al., 2003) 
demonstrated a statistically significant improvement in clinical endpoints (CD4 count and 
viral load). The studies tended to be limited by small sample sizes (Jones, et al., 2003; 
Molassiotis, et al., 2003; Parsons, et al., 2005), and the number of sessions, which numbered 
from eight to 12 (Jones, et al., 2003; Molassiotis, et al., 2002; Molassiotis, et al., 2003; 
Parsons, et al., 2005). In each of the latter three studies, attrition contributed to decreasing  
sample size over the courses of each study (all of which ranged from three to six months). 
Further this suggests that interventions that require many sessions with the therapist might 
tend to lose patients—and thus, efficacy—over time.   
The studies discussed suggest that CBT may help improve adherence to ART, but none of the 
studies tested whether symptom control could be effectively achieved using CBT. 
 
 43 
 
Table 2.1 Studies of CBT in ART.  
RCT: randomized controlled trial. CBT: cognitive behavioral therapy. ART: antiretroviral 
therapy. NS: non-significant. 
 
Study CBT 
Intervention 
n Design Variables Results Implications 
Murphy, et 
al (2002) 
Cognitive 
therapy to 
improve 
self-efficacy 
33 RCT Adherence 
by self 
report 
 
Self-
efficacy 
 
Higher self-
efficacy in 
intervention 
group; NS 
changes in 
adherence 
Authors suggest a 
larger trial.  
Molassiotis 
et al (2003) 
Education & 
counseling 
to maintain 
adherence 
to ART 
12 One 
group 
repeated 
measures 
Adherence 
by self 
report 
 
Intervention 
increased 
adherence 
from baseline 
Individualized 
education and 
counseling 
improves 
adherence to ART. 
 
Jones, et al 
(2003) 
CBT to 
improve 
coping: 
adherence 
implications 
174 RCT 
 
Adherence 
by self 
report  
 
Coping 
strategies  
Low-adhering 
women had 
less denial-
based coping. 
Intervention 
improved 
adherence in 
this group. 
 
Improvement in 
coping may 
improve 
adherence. 
Chiou, et al 
(2004) 
Education in 
side effect 
symptoms 
67 RCT 
3 arms 
Self 
esteem 
 
Hospital 
visits 
Hospital visits 
for side 
effects 
decreased in 
intervention 
groups. 
 
Education about 
side effect 
management may 
reduce hospital 
visits. 
Ironson, et 
al (2005) 
Self-efficacy 
& HIV 
disease 
markers 
56 RCT Self-
efficacy  
Self-efficacy 
correlated 
with 
improvement 
in CD4 and 
viral load; 
reduced 
distress in 
CBT group. 
 
CBT not targeted 
directly at side 
effects. 
Parsons, et 
al (2005) 
CBT to 
reduce 
substance 
abuse and 
increase 
adherence 
12 One 
group 
Adherence 
by self 
report 
Decrease in 
substance 
use 
No changes 
in adherence 
Short, small n 
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Furthermore, there was little use of behavioral techniques such as muscle relaxation. 
The reports suggest that most of the interventions focused on cognitive techniques such as 
education about ART.  
Gaps in the Literature 
 Cognitive-behavioral therapies have been tested in patients with cancer, HIV, and 
other diseases, both psychological and physical. The focus of this review has been on the use 
of CBT to reduce symptom intensity and frequency in patients taking ART. In the first 
section, six studies tend to suggest that adherence improves when a type of CBT is the 
intervention, but the specific elements of CBT in each study varied. Thus, it is somewhat 
difficult to draw conclusions about the most effective combination of techniques, which 
include cognitive (educational, skill-building, coping, guided imagery, self-persuasion) and 
behavioral (relaxation, distraction, behavior modification). However, when the literature on 
CBT interventions in cancer care is included, some combination of education/reframing, 
guided imagery, hypnosis, and relaxation emerge as preferred choices for designing an 
intervention. In the studies of HIV and CBT, adherence generally improved, but no study 
used side effect symptoms and adherence as a set of dependent variables.  
Summary 
 Infection caused by HIV is life-threatening and persistent. Viral suppression is the 
main goal of treatment, and leads to increases in CD4 counts and a reduction in opportunistic 
infections and HIV-related mortality. Moreover, the HIV genome is highly mutable, leading 
to the daily occurrence of drug-resistance mutations, which become more hazardous when 
medications are taken inconsistently. Thus, ART must be continued definitely. Yet adherence 
remains a problem. Forgetfulness, substance abuse and other behaviors may interfere with 
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adherence. Side effects from medication—experienced, or simply feared—also interfere with 
successful ART, whether because patients discontinue medications, or because their fears 
prevent them from undertaking ART in the first place. 
 Adherence education has become a standard of care in the management of HIV 
patients who consider taking, or who continue on, ART. Thorough, detailed instruction in the 
use of medications, dosing, how to manage side effects, and other aspects of medication 
taking has been shown to improve adherence. Psycho-educational interventions (e.g., 
counseling, individualized education) have also improved adherence in some studies, but not 
in all studies. Whether psycho-educational interventions will improve adherence remains an 
open question, and may depend on techniques that are used. 
 Side effects may interfere with medication taking, and this is also true in cancer 
chemotherapy. A significant body of research supports the use of CBT in the management of 
pain, anxiety, and nausea/ANV for such patients. The literature is silent on whether this 
affects adherence to ANT, but such interventions definitely improve patient comfort and 
sense of control. The literature contains four studies that looked specifically at whether CBT 
or related psycho-educational interventions could improve adherence. Results suggest that 
individualized CBT may improve adherence. Two studies were of such interventions, but 
with self-efficacy/self-esteem (SE/SE) and hospital visits as the dependent variables, and in 
general, improved SE/SE reduced hospital visits (assumed to correlate with disease severity) 
and improved CD4 counts. No study looked specifically at whether CBT could be used, as it 
has been in oncology, to reduce side effect symptom severity, and whether this would then 
affect adherence in a positive way. 
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Chapter 3 
Methods 
Research Design 
 This was a two group, randomized, controlled clinical trial. Both groups 
(experimental, control) received the standard of care (SOC) (adherence education) from their 
clinicians at their regularly-scheduled office visits. The experimental group also received the 
intervention at three time points (I1, I2, I3). Three categories of measurement (symptom scores 
by VAS, SF-36, and clinical laboratory data) were to be obtained at four time points. It was 
planned that each participant in the control group would be measured at study entry and three 
more time points, each about a month apart, until measurements were obtained for a three-
month period. Participants in the experimental groups would be measured at similar intervals, 
with some allowances for scheduling with the behavioral interventionist, and each 
measurement to be performed just prior to each of those three visits. The major advantage of 
experimental design is its power to resolve research questions by active, prospective 
comparison to controls, and thus to establish support for causality between the intervention 
and the outcome. Limiting and/or controlling for confounders is another advantage of the 
prospective design, and randomization contributes to that effort through the assignment of 
attributes across both groups (Polit & Beck, 2004). 
Setting 
The study was performed in an academic medical center infectious disease clinic in 
South-central Pennsylvania. The cognitive behavioral therapy (CBT) interventions were 
delivered in a quiet conference room with low lighting and comfortable chairs. The setting 
offered access to approximately 1200 HIV patients, 90% of whom were on ART at any given 
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time (J. Zurlo, personal communication, March 19, 2007). The center is part of the AIDS 
Clinical Trials Group (ACTG) and is a federally funded HIV treatment center. The clinic 
itself is also an outpatient cancer treatment center, with designated days during which 
HIV/AIDS patients are scheduled. 
Sample 
 Pre-trial discussion with the clinic’s physicians suggested that enrollment could be 
significantly limited if random sampling was utilized; therefore, convenience sampling was 
planned. The medical center’s institutional review (detailed further later) specified that 
participants would be pre-screened by a clinic physician or nurse, and if the patient agreed, 
the primary investigator (PI) could then explain the study in detail and offer the opportunity 
to consent. It was planned that participants would be randomized to the experimental or 
control group until the enrollment was filled. Rolling enrollment was to continue until 30 
participants completed the study. Power analysis is described in a later section. 
University- and institution-approved posters advertised the study. The PI attended 
clinic each day that the nurse case manager (NCM) reported that there would be potential 
participants available. (The clinic also mixed in many general infectious disease patients, so 
some days no or few HIV patients were scheduled.) On occasion, clinic physicians also 
notified the PI that a patient would be a suitable candidate for participation.  
Eligibility Measures  
The PI planned to recruit men and women, 18 years of age or older, who could read 
and understand English, and who could give an informed consent. Participants on ART were 
eligible if they affirmed that they suffered from one or more symptoms of nausea/vomiting, 
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fatigue, pain, and/or anxiety related to side effects. Participants had to have been on ART 
prior to study entry, but no minimum duration on ART was required.  
A demographic questionnaire (Appendix A) was used to collect data to describe the 
population and to determine eligibility requirements, and to confirm that participants were 
actively symptomatic. Data were collected on age, race, education, and other attributes and 
these were used to describe the population under study. Data on which of the four specific 
symptoms participants suffered from were also collected.  
Subjective Health Measures 
Specific symptom measures. Visual analogue scaling (VAS) was selected to 
quantify the four symptom variables (nausea, pain, fatigue, and anxiety). The four symptom 
variables selected are based on the author’s clinical experience when faced with patients who 
had or stated they would discontinue ART due to side effects.  
Table 3.1 
Symptom Variables 
________________________________________________________________________ 
 Nausea: to be understood as nausea, ―upset stomach,‖ or other unpleasant upper-
gastrointestinal sensations that the participant associates with medication use. 
 Pain: as felt by the participant; any pain is included. 
 Fatigue: to be understood as ―tiredness,‖ ―being wiped out,‖ or other terms, as felt by the 
participant. 
 Anxiety: or ―a sense of worry,‖ ―dread,‖ or ―feeling nervous‖ insofar as it relates to 
treatment or the disease itself (as it may be hard for participants to distinguish the two). 
________________________________________________________________________ 
 
Visual analogue scaling was developed to measure patients’ experience of pain 
(Keele, 1948). Subsequent refinements included the option of horizontal orientation and the 
use of straight lines without numerical marks, and with the use of verbal descriptors at either 
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end of the scale, reflecting the absence of a symptom to the perceived worst imaginable 
experience of that symptom (Gift, 1989). Cline, Herman, Shaw, and Morton (1992) proposed 
standardization of the VAS at 100mm, although other lengths have been proposed for other 
purposes, such as measurement of ―absolute‖ pain and ―comparative‖ pain (Carlsson, 1983). 
Wewers and Lowe (1990) reviewed how VAS has also been applied to the measurement of 
nausea, vomiting, anxiety, mood, dyspnea, a host of other subjective complaints. 
Reliability and validity of VAS. Visual analogue scales are reliable and valid. 
Brunier and Graydon (1996) tested the reliability and validity of VAS against a Likert scale 
in the measurement of fatigue. McCann and Boore (2000) used the 4-item vitality scale in the 
SF-36 as a measurement of the opposite state of fatigue, and as a validity check on scoring of 
the other measures in their study of fatigue in renal dialysis patients. In a study of general 
fatigue and breathlessness in healthy volunteers (Grant et al., 1999), the VAS demonstrated 
reproducibility coefficients of 78%, with correlations to physical demand measures ranging 
from .73-.82. Lingjaerde and Føreland (1998) tested 162 patients with seasonal affective 
disorder, and compared their VAS scales for global improvement after light-box therapy to 
the Montogomery-Asberg Depression Rating Scale (MADRS) and a scale for atypical 
depression symptoms (ATYP). Changes in VAS correlated closely with changes in MADRS 
(r=.85) and moderately well with ATYP (r=.64). Test/retest reliability was .96 for two 
consecutive ratings during a period in which participants reported no change. Muth, Stern, 
Thayer, and Koch (1996) designed a nausea assessment profile and tested it against VAS in a 
four-stage study involving over 1500 student volunteers. The purpose was to exhaustively 
describe nausea as a sensation, test the scale in a group affected by motion sickness versus 
control, and then to test correlation with VAS completed by participants. Correlation of .71 
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with VAS was found. In pain measurement, De Conno et al. (1994) tested 53 patients with 
cancer pain with 5 different rating scales, and a sixth at follow up after treatment of pain (to 
evaluate change). The VAS and the numerical rating scale showed the strongest association 
with absolute values of pain. Mottola (1993) suggests that VAS allows patients to render 
continuous, subjective, abstract sensations into data without having to describe these 
sensations in concrete terms. In this study, the VAS was used to measure nausea, fatigue, 
pain, and anxiety. Participants were asked to rate these symptoms a total of four times. At 
each time point a total of three scales were provided to allow the participants to rate three 
dimensions of each variable. The VAS instrument used in the study is shown in Appendix B. 
The anchors selected for the 4-week recall VAS were selected for their generality and their 
extremity, as patients can be relied upon to render their general sense of how badly they have 
felt or for how long in such terms (Gift, 1989). The 4-week recall was selected to coincide 
with both the SF-36 and the interim between measurements. 
In conclusion, high correlations with other types of scales and greater variability of 
scores have been seen in other studies of the VAS (Guyatt, Townsend, Berman, & Keller, 
1987; Price, Bush, Long, & Harkins, 1994; Winstead-Fry, 1998),  furthermore, the VAS 
seems to work well across various educable populations and for different symptoms (other 
than pain, which has been best studied) (Borjeson et al., 1997; Folstein & Luria, 1973; 
Guyatt, et al., 1987; Lee, Hicks, & Nino-Murcia, 1991; Winstead-Fry, 1998). 
The VAS has been used in measuring symptoms in studies of persons with HIV. 
Youle and Osio (Youle & Osio, 2007) utilized the VAS to measure pain in patients receiving 
acetyl L-carnitine as a treatment for neuropathy. Reductions of pain in the intervention group 
tended to be reflected in reductions in pain scores in both the McGill Pain Questionnaire and 
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the Total Symptom Score instruments, although the authors did not report specific correlation 
coefficients. Beal et al. (1995), in a study of the efficacy of dronabinol (Marinol®, Abbott 
Park IL) for anorexia associated with weight loss in persons with HIV used the VAS to 
measure appetite, mood, nausea, and vomiting. Fatigue was measured in HIV patients using 
VAS in a comparison study of methylphenidate and pemoline lessening that symptom 
(Breitbart, Rosenfeld, Kaim, & Funesti-Esch, 2001). The authors (Grant, et al., 1999) report 
that the Piper Fatigue Scale (PFS) was used as the primary measure of the dependent variable 
because it is well-validated. Changes in the Energy Subscale of the VAS for fatigue (VAS-F) 
showed significant improvement along with the changes in the PFS. The VAS-F is 18 items 
related to fatigue and energy, scored using VAS-type scales for each item (Lee, et al., 1991).  
Sensitivity. The VAS is sensitive to changes in symptom experience. Ohnhaus and 
Adler (1975), in a study of six subjects, compared the verbal rating scale (VRS) for pain to 
the VAS. They concluded that the VAS had greater sensitivity to changes in pain after the 
administration of pentazocine and attributed this sensitivity to the ―continuous‖ nature of the 
VAS, allowing for finer discriminations to be made by subjects in reporting changes. A 
similar study with similar findings using nausea as the dependent variable was undertaken by 
Borjeson et al. (1997). Again, VAS demonstrated great sensitivity to change, with a change 
in one step on a verbal category scale being associated with an average change of 20 mm on 
0-100 mm scales for nausea intensity, with good agreement between verbal and VAS scales. 
 There are other instruments that are specifically designed to measure symptom scores 
in persons with HIV. The HIV Assessment Tool was developed by Nokes, Wheeler, and 
Kendrew (Nokes, Wheeler, & Kendrew, 1994) and tested in 60 persons with HIV infection, 
43 with AIDS (defined by the Centers for Disease Control 1987 criteria), and 53 healthy 
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controls. The tool performs well, with test-retest reliability of .96, Cronbach’s alpha of .92, 
and good correlation with Karnofsky performance status (r = .51). Face, content, and 
construct validity were also established. The 34-item scale uses VAS-type scaling, but does 
not include questions specifically related to nausea, a symptom the author of the proposal 
specifically seeks to measure. It also inquires about many symptoms that, if medication 
related, suggest that a serious adverse event requires investigation and possible regimen 
change (e.g., skin rash, skin sores, cough, bleeding, etc.).  
 The Sign and Symptom Checklist for persons with HIV disease (SSC-HIV) 
(Holzemer et al., 1999) was expanded the number of symptoms and includes nausea as a 
symptom. It also includes a variety of pain items by region (e.g., headaches, chest pain) as 
well as a specific reference to ―fatigue‖ (as opposed to ―tiredness‖ in the HAT instrument). 
The collected symptoms better describe the general discomforts often reported from ART 
(e.g., gas, bloating) but still include many symptoms not under study here (e.g., wheezing, 
chills). Moreover, the questionnaire is scaled ―mild-moderate-severe‖ and thus loses the 
continuous scalability of scoring available with VAS. 
General health measures. The SF-36 was developed to measure a range of health 
outcomes by Ware and Shelbourne (1992), for the Medical Outcomes Study (MOS), a multi-
year research project designed to study patients with chronic conditions (Tarlov et al., 1989). 
The SF-36 is a self-administered instrument designed to measure interlocking domains. The 
SF-36 measures limitations of physical activities, pain, general mental health, limitations of 
usual role activities, vitality, and perceptions of general health (Ware & Sherbourne, 1992). 
 It should be noted that shorter forms related to multidimensional outcomes 
measurement do exist (e.g., Short Form-18, Short Form-20 [SF-20], SF-30-HIV), and indeed 
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such instruments are arguably more efficient to administer and would perhaps be easier to 
complete by study participants. However, Ware and Shelbourne (1992) present data that 
supports their assertion that some precision is lost in the use of the shorter scales, and that the 
somewhat longer SF-36 captures more real world types of limitations in function. For 
example, the SF-20 only offers one social functioning item. The developers found that adding 
a second item increased content validity for this sub-domain of overall function (Ware & 
Sherbourne, 1992). The developers also felt that the SF-20 did not adequately capture 
dimensions of health and function as these pertain to energy, lack of tiredness and similar 
concepts, and so added a vitality subscale. This addition was based on data from the National 
Health and Nutrition Examination Surveys (Stewart & Ware, 1991).  
 The SF-36 is well-validated, reliable, and is normalized to the general United States 
population (Hays, Sherbourne, & Mazel, 1995; McHorney, Ware, Lu, & Sherbourne, 1994; 
McHorney, Ware, & Raczek, 1993; Stewart & Ware, 1991; Ware, 1987). The use of the SF-
36 in the proposed study of HIV patients on ART would provide another set of measurements 
to compare to those VAS scores for specific symptoms (pain, fatigue, etc.) and provide 
numerical data on other quality of life dimensions, such as vitality, function, role, and 
emotion. There is one item on the SF-36 that asks if the respondent feels his/her health is 
better, worse, or unchanged from one year ago. This reflects the customary use of such 
instruments in longer-term studies such as the MOS. However, subsequent developments in 
the SF-36 have led to the production and testing of versions that allow for shorter terms of 
recall, and thus shorter intervals of change (Ware, 2005). The SF-36 was administered at each 
of the four time points described, and takes approximately 10 minutes to complete.  
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Table 3.2 
Explanation of the SF-36 Scoring System 
Concepts 
# of 
Items 
# of  
Levels 
Meaning of Scores 
Low High 
Reported Health 
Transition (HT) 
1 5 
Believes health is much 
better than a year ago. 
Believes health is much 
worse than a year ago. 
Physical 
Functioning (PF) 
10 21 
Limited in performing 
physical maintenance. 
Conceptually related to 
―ADLs‖ (activities of daily 
living). 
Performs such activities—
even the most vigorous—
without limits due to 
health. 
Role--Physical 
(RP) 
4 5 
Problems with work or 
other activities. 
Conceptually related to 
―IADLs‖ (instrumental 
ADLs). 
No problems with work 
etc. related to physical 
health. 
Bodily Pain (BP) 2 11 
Severe, limiting pain No pain or limitations due 
to pain. 
General Health 
(GH) 
5 21 
Evaluates health as poor 
and believes it will get 
worse. 
Evaluates health as 
excellent. 
Vitality (VT) 4 21 
Feels tired and worn out 
all the time. 
Feels full of pep and 
energy all of the time. 
Social 
Functioning (SF) 
2 9 
Physical and/or 
emotional problems 
severely interfere with 
social activities 
Normal social activities 
without interference. 
Role—Emotional 
(RE) 
3 4 
Problems with work or 
other daily activities 
resulting from emotional 
problems. 
No problems with work or 
other daily activities 
resulting from emotional 
problems. 
Mental Health 
(MH) 
5 26 
Feelings of nervousness 
and depression all of the 
time. 
Feels peaceful, happy, 
and calm all of the time. 
 
Note. ―Items‖ refers to the actual instrument questions, of which there are 36 and ―levels‖ 
refers to the number of items that contribute to that domain score. There are eight domains, as 
described above, and one ―health transition‖ score.  
 
Adherence Measures 
This study also used a VAS for participant estimates of average adherence over the 
past month (Walsh, Mandalia, & Gazzard, 2002), as well as 3-day recall (Chesney et al., 
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2000; Giordano, Guzman, Clark, Charlebois, & Bangsberg, 2004). The instrument designed 
by Chesney, et al. was structured, complex, and also inquired about specific reason for 
missing medication doses, and other data. Oyugi et al. (2004) employed the 3-day recall in its 
more common form: doses prescribed and doses taken over the last three days. That is how 
the instrument was used in this study. 
There are several measures of adherence that have been explored for use in research 
studies including biological assays of drug levels or for drug metabolites, pill counts, self-
monitoring/self-report, clinician estimates (Dunbar, 1980; Murri et al., 2004), electronic 
monitors (Diaz et al., 2001; R Gross, Bilker, Friedman, & Strom, 2001; Hinkin et al., 2002), 
and interviews, which may or may not include the use of scales (such as VAS, numerical 
rating scales, etc.) (Holzemer, et al., 1999; McPherson-Baker, et al., 2000).  
 Electronic monitoring is expensive (AARDEX_Group, 2007; Lamb, n.d.) and 
correlations with patient self-report is fairly good, (Melbourne et al., 1999) although patients 
tended to report a few percent higher adherence in the study by Melbourne et al.    
Unannounced pill counts (UPC) can be used, and are a less expensive measure of 
adherence. In a study that compared 3-day recall UPC and a VAS for adherence Giordano, 
Guzman, Clark, Charlebois, and Bangsberg (2004) found that the correlation between VAS 
and UPC was high (r=.76) and the difference between VAS and 3-day recall was non-
significant. Moreover, there was a trend toward inverse correlation between data from VAS 
and viral load measurements (r=-.49, p<.30), suggesting that participants who were taking 
their medications regularly and on time also tended to have better suppressed virus. Walsh, 
Mandalia, and Gazzard (2002) VAS adherence data correlated strongly with MEMS Caps 
data (r=.63, p<.001), pill counts (r=.75, p<.001), and an author-designed adherence 
 56 
 
inventory. Again, VAS was inversely correlated with viral load. This study uses a single VAS 
to measure medication recall ―since your last visit,‖ as it can be argued that this reflects real-
world adherence monitoring. Adherence was measured four times at T1, T2, T3, and T4. 
Adherence scores by VAS were rated on a 100mm scale. A score of 100 equates with 
reported perfect adherence. In this study the data from the 3-day recall was converted to an 
index: 
 
Doses taken 
-------------------------------  =  x 
        Doses scheduled 
 
Thus x becomes a number between 0 and 1, and represents a percentage. For example a result 
of 0.5 meant half the doses were taken.   
Control Measures 
 The use of side effect reducing medication (SERM) was measured, as it was 
considered a potential confounding variable. It was not hypothesized that participants in the 
intervention group will use less such medication than controls. Measuring the use of such 
medication would allow for statistical control of this variable in the analysis. A flow-sheet 
style diary (see Appendix C) was included in the measurement tools given to each 
participant. The diaries were designed to cover the approximately one-month span between 
each of the four measurements. Thus, each participant had to turn in three diaries. 
Participants were asked to record their use of various SERM, for nausea, pain, and anxiety. 
Participants were instructed that over-the-counter and prescription drugs were to be included, 
and they were told they did not need to specify which drugs they used. Drugs for fatigue were 
not included in the diary, because there are no drugs approved for the treatment of fatigue as 
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a symptom, by the U.S. Food and Drug Administration. The measure was intended to capture 
only the number of doses being consumed for the other three symptoms. 
 Immunologic Measures 
Viral load. This study used viral load data from chart reviews. Recommendations for 
the management of stable HIV patients call for testing serum virus levels and CD4 
lymphocyte counts every three months (Panel_on_Antiretroviral_Guidelines_for_Adults_ 
and_Adolescents, 2009). These data were to be collected at two time points including 
baseline, (T1, no more than one month prior to or after starting the study), and at the end (T4, 
within two weeks before or up to one month after a given participant’s completion). Although 
there was one research site, due to insurance requirements for individual participants, some 
participants had to obtain their tests from other laboratories. Because of this measurement 
variance from laboratory to laboratory variance was a concern. With advances in both 
technology and regulation this concern was believed to be less of a confounder than in the 
past. The planned timing of laboratory studies was discussed with the study site lead 
physician. 
Patients’ viral loads were expected to be reported from either branched-chain DNA 
(bDNA) assay or by polymerase chain reaction (PCR) assay. Branched chain DNA assay, a 
variant of PCR, might be more sensitive to low levels of virus, less dependent on taxonomy, 
and exhibit less error than PCR of the reverse-transcriptase gene (RT-PCR) (Grimes et al., 
2003). Today, bDNA and RT-PCR achieve detection of virus down to less than 10 
copies/mL, although commercial assays with detection limits from <200 copies/mL to <25 
copies/mL are more common, with the preponderance of laboratories providing detection 
limits on the lower end of that range. Detection limits are further discussed in Chapter 4. 
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Interlaboratory variation regionally. Regional variance in viral load testing was 
studied (Kellogg, Atria, Sanders, & Eyster, 2001). In that central Pennsylvania population, 
the authors were able to conclude that changes in measured virus levels less than 0.50log10 
were likely due to testing variation.  Changes equal to or greater than 1.00 log10 are considered 
to be clinically significant. Inter-laboratory variance was considered as a potential problem, 
and the findings related to such variation are discussed further in Chapter 4. 
Regulatory controls on variation. The Clinical Laboratories Improvement Act 
(CLIA) of 1988 provided a legal basis for the enforcement of compliance and competency 
standards in clinical laboratory testing. Although the U.S. Center for Medicare and Medicaid 
Services (CMS) has monitoring and enforcement jurisdiction over laboratory testing, third-
party accreditation agencies normally conduct routine evaluation of competency and 
compliance (CMS, 2006). (The College of American Pathologists [CAP] and Joint 
Commission for Accreditation of Healthcare Organizations [JCAHO] are two of the major 
accreditation agencies in this regard [N. Sheaffer, personal communication, December 7, 
2006.]) All of the laboratories that participants might use would be subject to CLIA, and this 
fact provided a modicum of certainty that interlaboratory variation would be minimized. 
CD4+ lymphocyte (CD4) count. This study used CD4 counts from chart reviews at 
T1 and T4., and—since these are usually drawn together—the same timing criteria discussed 
in the section on viral load.  Concerns about variation among laboratories applied here as 
well. ―Single platform‖ flow cytometry (FC) analysis has recently become a more common 
means of measuring CD4 counts. Such systems have used cell-sized, fluorescent-tagged 
beads of fixed amounts as controls added to the FC sample, enabling an actual counting of all 
signals (C. Boyer, personal communication, December 7, 2006; Beckton, Dickinson, & 
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Company, 2003). Single-platform testing has been shown to be a more accurate measure of 
absolute THC in whole blood (O'Gorman & Nicholson, 2000). The laboratories used in this 
study are CLIA-certified (C. Boyer). Against the standard calibration standards no more than 
2% variance is likely. Laboratories in each geographic location each tested a sample with a 
CD4 count of 100, the widest potential variance between their results would be 98-102 
cells/mm
3
 (N. Sheaffer, personal communication, December 7, 2006). 
Standard of Care and Experimental Intervention 
The standard of care (SOC): adherence education. The importance of adherence 
and recommendations for adherence training were established in Chapter 2. The SOC for this 
study is ―usual care,‖ which is described in this section.   
 During the practical coursework prior to the proposed study, from February to April 
2006, this PI conducted observations of clinical encounters at the treatment sites that were 
approached for the present study. All clinics were Ryan White-funded entities. Two of the 
fours clinics were hospital affiliated, one was a satellite site of a major academic medical 
center, and one a private, non-profit clinic.  
During the observation period, the author recorded notes on 10 visit encounters for 
HIV care. The clinicians providing adherence assessment and education were two physicians, 
three nurse practitioners (NP), a registered nurse (RN) and a pharmacist. This group is 
reasonably believed to constitute a representation of the ―average‖ specialist clinician treating 
HIV patients.  
 Three types of occasions for adherence education were observed. The first occasion 
for education is when planning to start a regimen. This may include discussions in visits prior 
to the actual prescription. The second occasion is at follow up, to monitor adherence and 
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repair any problems. The third is when a regimen is changed (all or part). Adherence 
education was more formalized for the new patient, or for the patient facing a significant 
regimen change. For patients already on ART for some time (months, years), the assessments 
focused on most of the major areas discussed by Golin et al. (2004), but with less emphasis 
on touching each point outlined by that group. The assessments tended to follow a model 
similar to that used in medical history taking, for example: clinicians often asked a screening 
question such as ―Are you taking all of your meds ok?‖ Any equivocation would prompt 
further questions, e.g.: ―Are you taking your Combivir with food?‖ or ―Is it the taste of the 
Norvir that’s keeping you from taking it?‖ and so on, until a ―diagnosis‖ of the adherence 
issue was established.  
During the observations, clinicians missed some features of adherence education 
outlined by Golin, et al. (2004) in some visits. The assessment of adherence was sometimes 
approached in very different ways by different clinicians. This observation was recorded in 
all the regional clinics examined. Since both the control group and the experimental group 
will continue visiting their clinicians as scheduled, this SOC will be common to both groups.  
The independent variable: the intervention protocol. The intervention consisted of 
three CBT sessions. The  first session was designed to impart the basic therapeutic thrust of 
CBT which includes using thoughts to frame the experience and reinforce an internal sense—
or locus—of control (A. T. Beck, 1976; J. S. Beck, 1995; Kalichman, 1995), and to discuss 
individual participant concerns, symptoms, etc. The cognitive piece of CBT was focused on 
assessing those concerns, and on working with the patient to establish a knowledge base 
about the purpose of the encounters. This teaching did not focus on knowledge about ART. 
That had already been done by the treating clinician, nurse, or pharmacist in a medical 
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setting. Rather, the purpose of this encounter was to inquire about perceived psychosocial 
limitations, how symptoms were being experienced, and their meaning to participants. 
Perceived limits to adherence, anxiety about medication taking, and other treatment-related 
issues were primary (K. Bakke-Friedland, personal communication, April 21, 2006).  The 
session content is detailed in the following sections. Participants received reminders about 
appointments with the behavioral interventionist (BI) by telephone call to a number of their 
choice. The PI made all such contacts. 
Timing of the first session. In participants assigned to the experimental group this 
first visit was planned to occur within two weeks of assignment. This was to allow for 
scheduling that would be convenient to participants, but assure that they also moved along at 
the same pace in the study as those participants in the control group.  
Detail: the first visit.  This was an introductory session. The items below were 
interspersed throughout the session, but are listed below in their approximate order of address 
within the session: 
 CBT, its relevance to adherence.  
 Introduction, and getting to know the participant, 10 minutes 
 Self-defeating thinking, 12 minutes 
 How automatic thoughts affect our mood and behaviors, 12 minutes 
 Participant personal sharing, 10 minutes 
 Plan for following sessions, 6 minutes 
Timing of the second session. The second visit was scheduled about three to four 
weeks after the first session. 
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Detail: the second visit. This was designed to begin to implement the CBT strategies. 
Format was similar. 
 Review and update with the participant by the behavioral interventionist (BI), 10 
minutes 
 Introduction to progressive muscle relaxation (PMRT), 10 minutes 
 Coached session of PMRT, 15 minutes, (recorded) 
 Questions and personal sharing, 10 minutes 
 Plans for next session, 5 minutes 
The PMRT session was recorded, and each participant was given a compact disk 
(CD) with the session for use in private practice sessions at home or elsewhere. No 
restrictions were placed on how often or where they could listen and practice. It was 
suggested they use the practice CD daily or at least several times a week.  
Progressive muscle relaxation training. This involves the coached tensing and 
relaxation of groups of muscles. The tensing helps focus the person’s attention to the area. 
The person is then coached to relax the muscles just tensed. The original procedure could 
require 30-45 minutes (Bernstein & Borkovec, 1973). Later variations have been adapted to 
require as little as a few moments to several minutes to 20 minutes or more (Schweitzer & 
Miller, 2005). Bernstein and Borkovec offer very clear guidelines for PMRT. The present 
study modified these conditions.  In this study we used the ―seven muscle group‖ procedure 
(Bernstein & Borkovec, 1973, Chapter 7), as this was felt to provide a reasonably thorough 
session while preserving time. It requires 10-12 minutes. It was judged that participants 
should to be able to use PMRT as often as necessary, and that brevity could contribute to 
more frequent use. No literature was found that contradicted such an assumption. 
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Timing of the third session. The third session followed the second session by about 
three to four weeks. 
Detail: the third session. This was designed to move the control of the techniques to 
the participant, review and follow up on any issues during the interim. 
 Review and update with the participant by the BI, 10 minutes 
 Introduction to guided imagery (GI), and exploration of participant imagery models, 
10 minutes 
 Coached session of GI, 15 minutes 
 Disengagement, 15 minutes 
Guided imagery. GI is a technique in CBT, and is the use of live coaching to help 
patients develop assistive, positive, or otherwise motivational imagery. Alternatively, the 
imagery may be relaxing and anxiety-relieving, or may be intended to force vicarious contact 
with feared events for the purpose of confronting unpleasant thoughts and then reframing 
them. The coaching of imagery is inspired in its development by the patient and how he 
symbolizes his world, but is guided by the therapist (J. S. Beck, 1995). 
Although effect sizes are moderate (.50), PMRT and GI have been found to be 
effective in the management of similar symptom clusters (nausea, anxiety, etc.) associated 
with antineoplastic therapy (Burish, et al., 1987; Burish & Tope, 1992; Carey & Burish, 
1987; Simonton, Matthews-Simonton, & Sparks, 1980), and were believed to be reasonable 
choices to begin exploring CBT in patients with HIV who are undergoing ART.  
Duration and Personnel 
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 All sessions were scheduled for 50 minutes, the industry-standard counseling session 
(Kathrine Bakke-Friedman, personal communication, June 16, 2006). All CBT intervention 
sessions were administered by a Pennsylvania-licensed psychologist.  
Safety Issues Relative to CBT  
 During CBT sessions, it was considered possible that some participants might 
experience psychic discomforts related to specific concerns, and could include: 
 Expressions of suicidal ideation 
 Expressions of harm toward others 
 Hallucinations, other manifestations of psychosis 
 Unpleasant memories of suppressed events such as rape, battery, other forms of abuse 
 Undiscovered psychological pathology that emerges during training sessions 
 Any behavior, expression, or other event that, in the opinion of the therapist, should 
prompt an evaluation, as detailed in the next paragraph 
 Such events would prompt the primary investigator (PI) and the BI to discuss 
disposition of such participants. The plan for such events was that participants would be 
offered referral to inpatient or outpatient services, as appropriate, based on the clinical 
judgment of the team, in consultation with the participant’s treating clinician. Participants 
were advised prior to entry that such referral was not part of the study would be pursued 
within their ordinary treatment channels. (All patients of Ryan White-funded HIV services 
are covered in some way for such professional services for mental health. This does not rely 
on specific insurance plans, although such plans may be used to pay for mental health 
services.) All study participants were evaluated by the PI prior to entry for access to mental 
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health services. Participants were advised that they could withdraw at any time without 
penalty. 
 Other issues that could come to the attention of the PI or research team and demand 
reconsideration of further participation included: 
 Hospitalization for opportunistic infection or other cause (e.g., myocardial infarction): 
termination of participation: if hospitalization would exceed one week 
 Any opportunistic infection not requiring hospitalization (additional burden of 
medications or procedure may make orderly follow up impossible): re-evaluation of 
participation 
 Symptoms such that a participant withdraws from ART: termination of participation 
 Relapse of substance abuse behavior that interferes with participation in study visits 
termination of participation if behavior is associated with missing any study visit  
Brief hospital stays, a single episode of substance abuse followed by renewed 
abstention, or other relatively minor events were not considered to be reasons to discontinue 
participation, if he/she wished to continue. Antiretroviral therapy is often continued in such 
circumstances. It was reasonable to consider that the CBT intervention could even contribute 
to continued use of ART by patients experiencing such short term difficulties. 
Procedures for Data Collection 
 After consent and randomization, each participant was provided with the first set of 
measurement tools and allowed time to complete them while waiting during the medical visit. 
In a few cases, time constraints made it necessary for the participant to complete and return 
the measurement tools to the researcher via a self-addressed, postage paid envelope. In all 
cases, participants were provided with verbal instructions read from the instrument. The 
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instructions were also available for the participant to read later  if needed. Participants in the 
control group were asked to complete and return the measurement tools at specific time 
points. Thus, two or three sets of measurement tools were given to the control group 
participants after informed consent was obtained. 
 Each set of measurement tools included a symptom VAS, an SF-36, and an adherence 
tool (both VAS and 3-day recall). A SERM diary was also include in each set. Each tool, in 
addition to including instructions on use, was individually marked with the participant 
number, the measurement number, and the date completed. Sets of measurement tools given 
to the control group participants for completion at end of 30-, 60-, and 90-days, were further  
marked with the specific dates to be completed. In addition, each set of tools was color coded 
using tinted paper, to provide further clarity. Participants in the experimental group also 
received calendars with instructions on how to record practice sessions of PMRT (for 
measurements T3 through T4). However, these were not provided until they had actually 
attended the second session, and were individually dated for each participant. As a rule, all 
instruments’ instructions were discussed with participants. 
 There were four planned measurement events. The planned timing is shown in the 
scheme in Figure 3.1. In planning, it was believed that scheduling could conform somewhat 
closely to this scheme. In practice, these times were difficult to adhere to. More on this is 
discussed in later chapters. As was noted, telephone reminders were used frequently, both to 
remind control group participants to complete their measurements, and to remind 
experimental group participants to attend their meetings with the BI, as well as to remind 
them to complete their final surveys.  
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Participants entering the study were measured at T1, study entry, and then again at T2 
(1 month into the subject’s participation in the study), T3 (two months into the study) and T4 
(three months into the study, at its end). The measurements in the experimental group were to 
be timed similarly, although getting measurements before the intervention visit, even 
immediately before, was considered paramount, as it was believed that measurements 
immediately after the intervention visit would be artificially improved (lower symptom 
scores, higher SF-36 scores) because of ―priming‖ recollections with a recent pleasant 
experience (the intervention visit). The data collection plan is shown in Table 3.2. 
 
 
 
Figure 3.1 Study Scheme.  
 
 
Notes: T1: Time 1 (study start); T2: Time 2 (1 month); T3: Time 3 (2 months); T4 
Time 4 (study exit). I1: Intervention 1 (scheduled within 2-4 weeks of study start); I2: 
Intervention 2 (scheduled 2-4 weeks after first intervention); I3: Intervention 3 
(scheduled 2-4 weeks after second intervention).  
 
 
 
Accrual & 
Consent 
Randomization 
T1 T2 
CONTROL 
EXPERIMENTAL 
I1 I2 I3 
T3 T4 
   Month  0                       1                     2                     3 
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Table 3.3 
Data Collection Plan 
 Study Start  
(Time 1) 
1 Month 
(Time 2) 
2 Months 
(Time 3) 
Study Exit 
(Time 4) 
Group C E C E C E C E 
Measures VAS VAS VAS VAS VAS VAS VAS VAS 
 SF36 SF36 SF36 SF36 SF36 SF36 SF36 SF36 
   SERM SERM SERM SERM SERM SERM 
    PRAC  PRAC  PRAC 
 CD4 CD4     CD4 CD4 
 VL VL     VL VL 
How 
collected 
In 
person 
In 
person 
Mail 
In person 
(Before 
session) 
Mail 
In person 
(Before 
session) 
Mail Mail 
Note. C = control group; E = experimental group; VAS = visual analogue scales for nausea, 
pain, fatigue, anxiety; SF36 = Short Form-36; SERM = side-effect reducing medication diary 
sheet; PRAC = practice diary calendar; CD4 = lymphocyte counts; and, VL = serum virus 
level.  
 
Ethical Considerations 
Approvals. Institutional Review Board (IRB) approval was obtained from Duquesne 
University and from Penn State University College of Medicine (Hershey, PA). Informed 
consent (Appendix D, approved by both IRBs) was presented to subjects after they expressed 
an interest in the study but before randomization. Participants and clinicians were reminded 
that changes in medical regimens as deemed necessary, as well as the use of SERM, should 
proceed as they normally would, and was believed would reflect real-world demands of ART 
as well as supports participants’ safety. The consent form was explained to each participant, 
and each was given ample time to read the form. The investigator completed National 
Institutes of Health Human Subjects Protection Education for Research Teams on February 6, 
2004, on file with Duquesne University School of Nursing. Penn State employs a proprietary 
computer-based tutorial that concerns human subjects’ protection, and this was completed by 
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the PI as part of the IRB approval process at that institution, and is on file with the Human 
Subjects Protection Office in the College of Medicine. 
Health Insurance Portability and Accountability Act (HIPAA) and data security. 
Approvals for information security were obtained during the Duquesne University IRB 
approval process. At the beginning of their participation individuals were assigned a code 
number, sequentially generated from ―01‖. All materials related to the participant, such as 
mailed surveys, displayed only that number, and no name. Data files displayed the number 
only. The only place names and numbers appeared together on any document or file was in 
the data folders, kept in a locked cabinet at the PI’s university office. The number was 
generated at the same time as informed consent was obtained and followed each participant 
throughout the study. Once used, numbers were discarded if a participant left the study; thus 
all numbers were unique. 
Initially, mail communications were thought to be a potential security concern (since 
a name would be on each envelope); however, all participants agreed to receive mail 
communications and did not express any special concern about that. Efforts were made to 
avoid using terms like ―HIV‖ ―AIDS‖ or ―antiretroviral‖ on any printed materials (such as 
measurement instruments) and in phone messages/reminders.  
 A ―master list‖ in Microsoft Excel contained no reference to the terms ―HIV,‖ 
―CD4,‖ or any other health information, and served to link numbers with names, progress in 
the study, and other tracking information. This was necessary to maintain the study, and the 
data were kept on removable a removable medium, not part of a laptop hard drive, and kept 
with the data folders, as well. The BI completed a confidentiality agreement (Appendix E). 
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All identifiable data including raw data files and consents was destroyed at the end of the 
study (approval of dissertation and final filing of electronic dissertation). 
Payment to participants. Participants were paid $10 for each set of surveys 
completed, to help defray costs of transportation, childcare or other inconvenience. Payment 
was the same regardless of whether a participant was in the control or experimental group. 
Cash was paid during in-person encounters. Checks were issued from a private account for 
mailed surveys. 
Data Analysis 
The independent variable under study is the introduction of the experimental 
intervention. The dependent variables are summarized in Table 3.3. These include potential 
confounding variables. Descriptive statistics were performed, and the groups examined at T1 
for equivalence. The data were also examined for normal distribution of scores and variances 
between groups.  
Statistical tests. The study examined three hypotheses, one directional and two non-
directional, and also considered an array of potential confounders or covariances (e.g., SERM 
use). The intervention and measurements was planned to occur over three months. Multiple 
analysis of variance (MANOVA) and repeated measures analysis of variance (RM-ANOVA) 
were considered, as these would account for between-group differences, within-group 
differences over time, and the effects of variables on one another, as well as reduce the 
likelihood of Type I error. Use of these tests, however, depends on the data meeting criteria 
for parametric testing and would have required a very large sample size (Field, 2009, P. 
Ricci, personal communication, September 11, 2009).  A study designed as a proof-of-
concept trial would not submit to these tests, given the small sample size. In addition, Polit 
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and Beck (2004) and Field (2009) argue that multiple ANOVAs do not truly test the effects 
of multiple variables among groups, they merely repeat the same analysis with different  
Table 3.4 
Dependent and Control Variables  
Variable &  
number of dimensions Measure and Scale Analysis of 
Nausea 3 dimensions VAS 0-100 mm Primary hypothesis 
Pain 3 dimensions VAS 0-100 mm Primary hypothesis 
Fatigue 3 dimensions VAS 0-100 mm Primary hypothesis 
Anxiety 3 dimensions VAS 0-100 mm Primary hypothesis 
Physical Function  SF-36 0-100 normative Primary hypothesis 
Role Physical SF-36 0-100 normative Primary hypothesis 
Bodily Pain SF-36 0-100 normative Primary hypothesis 
General Health SF-36 0-100 normative Primary hypothesis 
Vitality SF-36 0-100 normative Primary hypothesis 
Social Function SF-36 0-100 normative Primary hypothesis 
Role Emotion SF-36 0-100 normative Primary hypothesis 
Mental Health SF-36 0-100 normative Primary hypothesis 
Adherence VAS 0-100 mm Primary hypothesis 
Adherence 3-day recall  
Doses taken/Doses 
Prescribed 
Primary hypothesis 
Viral load Log 10 Primary hypothesis 
CD4 Absolute count Primary hypothesis 
Doses of SERM Days in period/Doses taken 
(Arithmetic average)  
Control variable 
Times CBT practices number of participant-
initiated practice CBT 
sessions 
Control variable 
Note: VAS = visual analogue scales for nausea, pain, fatigue, anxiety; SF36 = Short Form-
36; SERM = side-effect reducing medication diary sheet; CD4: lymphocyte counts; the 
number of dimensions includes a VAS for each of level of the symptom in general, the worst 
experience of that symptom, and the average duration of the symptom, over the prior month. 
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factors without the ability to examine the effect of simultaneity that actually does occur with 
multiple independent variables (e.g., our ―control variables‖, participant attributes).  Doubly-
multivariate analysis is another method to test several related, dependent measures, repeated 
at fixed time points. However, the number of dependent variables cannot exceed the number 
of participants in that method (P. Ricci, personal communication, September 14, 2009), 
which was the case in this study. Parametric testing rests on assumptions of independence, 
equal variances, and normality of scores. Because these could not be assumed until the data 
were actually analyzed, post hoc, non-parametric testing was also planned. 
Hypotheses of extent of change. This study hypothesized that changes (effect sizes) 
would be at least one standard deviation (SD) of 20 mm on the VAS. Various ranges of effect 
size for various psychological interventions in oncology symptom management are .17 to .64 
(Meyer & Mark, 1995), and .31 to .49 (Tatrow & Montgomery, 2006). An effect size of .50 
could be expected. However, in other studies limited to using VAS as a measurement tool, 
effects sizes were much larger, perhaps because of the sensitivity of VAS to changes in 
symptom levels (Gift, 1989; Grant, et al., 1999). Several such studies are summarized in the 
next paragraph. A change of 20mm (20%) has been considered a clinically significant change 
in other studies (Nusstein, Steinkruger, Reader, Beck, & Weaver, 2006; Syrjala, Donaldson, 
Davis, Kippes, & Carr, 1995; Wang, Belza, Thompson, Whitney, & Bennett, 2006),  
Power analysis. The study proposed to enroll 15 per study group. 
Using the formula: 
      1 - 2 
ES = ------------ 
                                                               
 73 
 
Using a hypothetical average score of 50 mm, the experimental change would be assumed as 
a mean of 30 mm. 
 
      50 - 30 
ES = ------------ 
                                                               
 
        20 
1.00 = ------------ 
                                                              20 
 
Using an effect size of 1.00 we can calculate that 15 participants in each group would provide 
a power of .80. The study aimed to recruit 15 participants for each group (K. Kjelrulff, 
personal communication, July 3, 2007; Lenth, 2006; Lipsey, 1990) 
Level of significance. One-tailed testing with the significance level set at .05 was 
planned for the first, directional hypothesis concerning VAS symptom scores and SF-36 
scores, and two tailed testing was selected for the non-directional hypotheses concerning 
adherence and CD4 counts/viral loads.  The use of a level of .05 is a common level of 
significance for studies of psychobehavioral interventions in nursing and psychology studies 
(Polit & Beck, 2004).  
Software. The analysis used version 16.0.1 of SPSS
TM
 for the overall analysis. 
Scoring for the SF-36 was done on Microsoft Excel 2007
 TM
, with author-programmed 
formulae based on the scoring algorithms in Ware, Kosinski, & Gandek (2005). 
Summary 
 This was a randomized, controlled clinical trial that planned to recruit 30 participants 
(approximately 15 in each arm). Each group of HIV-infected participants would receive the 
standard of care (adherence education). The experimental group would meet with the BI, who 
would deliver three sessions of CBT with an emphasis on participant-practicable techniques 
such as PMRT and GI, chosen for their demonstrated ability to reduce arousal, and shift locus 
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of control internally. This was done to examine whether or not experimental group 
participants would score lower on VAS of nausea, pain, fatigue, and anxiety, and whether the 
intervention would have any effect on adherence, CD4 or viral load. Males and females 18 or 
older were recruited from an infectious disease clinic. Participants had to be on ART for any 
duration, and to have one or more of the symptoms being measured. In addition, general 
health measures, adherence to medications, SERM use, and laboratory data were to be 
collected at four time points over three months. Planned analyses included repeated measures 
ANOVA, with non-parametric testing used for the post hoc analyses. 
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Chapter 4 
Results and Data Analysis 
 This chapter reports the findings, and begins with a report of the sample that was 
recruited. The final sample is described and the composition of the experimental and groups 
follows. The statistical analysis is introduced. Finally, the results and analysis of data are 
organized according to hypotheses tested.   
Recruitment and Study Completion 
Recruitment took place over an eight month period from September 16, 2008 to June 
1, 2009. The target enrollment was 30, with an estimated number per group of 15. Final 
enrollment was 33, with 9 in each group completing the study. During the recruitment period, 
384 individuals were screened by clinic staff, and 57 were approved for recruitment. This 
captured 15% of the clinic attendance. Of these, 33 agreed to participate. No specific data 
were collected on why potential participants declined participation but the most common 
reasons noted were disinterest and/or lack of symptoms. Table 4.1 displays details about the 
participants as they progressed to the end of the study. A total of 18 (55%) of the enrolled 
participants completed the study; 15 or 45% of those enrolled did not complete the study. 
Participation of those listed as ―Suspended‖ was finally discontinued by the investigator 
because the intervention became unavailable due to the loss of the behavioral interventionist.  
This was because of unexpected and personal reasons.  
No data were collected on why participants left the study, beyond the reasons stated in Table 
4.1. Participants lost to follow-up (LTF) were contacted more than eight times on average, 
and generally for 30 days before no further contact was attempted. In most cases, the staff 
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was unable to supply any additional information on why such participants could not be 
contacted. 
Table 4.1  
Summary of Enrollees and Withdrawals  
Group N enrolled N completing 
% Completing Reasons for  
Leaving the Study 
 
Control 
 
12 9 75 
LTF   3   
Experimental 21 9 42 
LTF  3 
Scheduling 
problems 2    
Medical   2 
Died   1 
Incarcerated   1 
Suspended 3* 
 
Total 
 
33 18 55 
 
15 
Note. *Suspended when the enrollment was halted. LTF = lost to follow-up. 
 
 
 
 
Figure 4.1 Summary of Recruitment and Retention 
 
 
 
 
 
 
 
 
Number of 
clinic patients 
screened by 
staff 
 
384 
Number of 
clinic patients 
approached 
for recruitment 
 
57 
Number of 
patients 
consented to 
study 
 
33 (58%) 
Number of 
participants 
who 
completed the 
study 
 
18 (55%) 
Not 
consenting 
24 (42%) 
Not 
completing 
24 (45%) 
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Description of the Sample 
Participants who completed the study are described in Tables 4.2 and 4.3. The sample 
was predominantly Caucasian males, with the exception of one Caucasian female participant. 
Experimental designs assume that randomization will produce groups that are comparable. 
This study used a randomized design until 29 participants were enrolled. At this time losses 
to follow-up already approached approximately 27% (attempts to contact recent lost 
participants were continuing), and assignment was changed to a stratified randomized design. 
The remaining four enrollees were all assigned to the experimental group, however none 
completed the study and thus, by default, a true randomized design was preserved in the final 
data set. A t-test of between group differences at baseline suggests that the groups were not 
significantly different.  The majority of participants were white males. 
 
Table 4.2  
Demographic Composition of the Sample 
 
 
 
 
 
 
 
 
 Frequency Percent 
Male 17 94.4 
Female 1 5.6 
Caucasian 15 83.3 
Caucasian Hispanic 1 5.6 
African American 2 11.1 
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Table 4.3 
Descriptive Statistics of the Total Sample (N=18).   
 
Note. SD: standard deviation. ART: antiretroviral therapy. CD4: CD4 lymphocyte absolute 
count. VL: viral load. Log10VL: VL in log10. *Rounded to nearest .01. 
  
Completeness of data. The demographic data were 100% complete. More than 90% 
of the surveys were completed and returned. Of the surveys that were collected >95% of the 
items were completed; that is, the VASs (symptom scores and adherence), and the items on 
the SF-36. About 85% of the SERM-use diaries were returned, many blank, and blank diaries 
were counted as ―no SERM used.‖ Complete sets of laboratory data were missing on all with 
the exception of six participants, and many had neither beginning nor ending reports. The 
most common reason for missing laboratory data was that the participant had not reported to 
a laboratory for the sample to be drawn. The second most common reason (only two cases) 
was that the laboratory itself had a problem with the sample (e.g., test not run, sample ruined, 
etc.). There were six complete observations for CD4 and viral load (VL), with both study 
entry and study exit values reported. The standard deviations (SD) for CD4 and VL for these 
pairs of observations were high, and given the low number of complete sets of laboratory 
 N Range Min. Max. Mean SD Variance Skewness* 
 
       Statistic 
Std. 
Error 
Age in years 18 16 40 56 46.8 4.2 17.4 .67 .54  
ART # of 
Weeks 
18 467 13 480 200.2 160.5 25772.5 .58 .54 
Starting CD4 13 1241 121 1362 544.2 352.2 124069.5 1.10 .62 
Starting VL 18 147 0 147 58.6 42.9 1838.9 -.038 .54 
Start 
Log10VL 
18 2.2 0.0 2.2 1.4 .9 .79 -1.05 .54 
Valid N  18         
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measures, imputation analysis with an expectation-maximization (EM) algorithm was used to 
replace missing values with plausible ones. Thus several values in the laboratory data were 
imputed from the data that was available, based on estimates of likelihood.  Given the low 
number of participants, this imputation of laboratory values had to be done for statistical 
power when analyzing that data. (P. Ricci, personal communication, September 20, 2009).  
In analyzing for differences between the groups at the start of the study, imputation 
analysis did not change results for sex, race/ethnicity, age, and ART duration in weeks. 
Imputation analysis did change results for CD4, viral load count and viral load by log10. The 
groups were compared at study start, both before and after the imputation correction was 
applied to the laboratory data.  As shown in Table 4.4, the experimental and control groups 
were equivalent at the beginning of the study.  
Table 4.4 
Group Comparison, Independent Samples Test: Post Imputation Analysis of Missing Values 
Attribute 
Between Groups Sig. 
(2-tailed) 
Difference 
Sex .347 NS 
Race/Ethnic .313 NS 
Age .957 NS 
ART Weeks .838 NS 
Starting CD4 .981 NS 
Starting VL .328 NS 
Start Log10VL .517 NS 
 
Note. Results are based on data set with imputation analysis, reflected in the clinical 
measures for which there were missing data. ART: antiretroviral therapy. CD4: CD4 
lymphocyte absolute count. VL: viral load. Log10VL: VL in log10. NS: not significant.  
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Analysis of the Sample for Statistical Testing 
Using Lenth’s (n.d.) Power Analysis for ANOVA Designs (Java applet) the following 
numbers of participants are suggested for effects sizes of .50, .75, and 1.00: eight, four, and 
two, for each group, respectively. Lenth notes that this applet is limited in its ability to 
calculate samples sizes for multiple-measure designs. This limitation was addressed by taking 
each measurement interval as a ―level‖ of measurement in the factor table, the number of 
participants using Lenth’s applet describes eight levels in all.  Hence for the number of 
subjects in this study an effect size of .1.00 size was required to achieve a power of .80. As 
was noted in Chapter Three, the study’s power analysis was originally based on a clinically 
significant change of 20mm on symptom VAS scores, and on 30 participants completing the 
protocol.  Of the 33 participants originally enrolled in the study, only 18 completed the study. 
Enrollment was halted due to a lack of additional eligible patients.  Some pairs of laboratory 
data were missing. Imputation was performed to create a data set that would respond to 
analyses. The final data set did not fully meet criteria for parametric testing. There was no 
random sampling, and values for skewness and kurtosis exceeded suggested limits. The 
planned comparison for this study was based on parametric testing. For parametric testing to 
be valid there are several criteria that should be met. The data must be normally distributed, 
display homogeneity of variance, and be independent (Field, 2009). Frequency analysis was 
performed on all of the variables in the sample including computation of skewness and 
kurtosis. To summarize the results of this analysis, mean skewness and mean kurtosis are 
reported in Table 4.5 for each of the four measurement points for the symptom scores 
measured by a VAS. Values of skewness and kurtosis close to zero suggest more normal 
distribution of scores. In smaller samples, values of skewness and kurtosis were converted to 
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z-scores; those not exceeding a SD of 1.96 generally conformed to normality. Note that in 
this sample, z-scores for kurtosis generally exceeded 1.96; however, in a sample this small, 
even values that somewhat exceed 1.96 (2.0 - 2.5) do not necessarily stamp the sample as 
non-normal (Field, 2009).  
Table 4.5  
Symptom Scores: Mean Skewness and Kurtosis  
Average z -score 
Skewness
SD
Average z -score 
Kurtosis
SD
Symptom 
measures T1
-0.03 1.69 -0.40 2.11
Symptom 
measures T2
0.14 1.89 -0.39 2.35
Symptom 
measures T3
-0.09 2.29 0.27 2.43
Symptom 
measures T4
-0.28 1.78 -0.10 2.39
 
Note. SD: standard deviation; T1: time 1, at study entry; T2: time 2, measurement at 1 month, 
or just prior to the first with the behavioral interventionist; T3: time 3, at 2 months, or just 
prior to the second visit with the behavioral interventionist; T4, time 4, at 3 months and study 
completion 
 
 Regarding the assumptions of parametric testing, it can be said that the groups were 
independent, that some variances between the groups were not equivalent (sex, race/ethnicity, 
ART duration, starting VL count), and that the distribution of symptom measurement scores 
did not achieve normality.  
Hypothesis Testing  
 There were three hypotheses: 
1. Participants who received the cognitive-behavioral therapy (CBT) intervention would 
report a reduction in side effects, compared to participants who only received the standard 
of care (SOC). 
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2. Participants who received the CBT intervention would show a difference in adherence 
compared to those who only received the SOC. 
3. Participants who received the CBT intervention would show a difference in CD4 and 
VL compared to those who only received the SOC. 
The first hypothesis was analyzed in two parts. First, side effects data from the third 
(T3) and fourth (T4) measurements of nausea, pain, anxiety and fatigue are reported. Second, 
general health data from the third (T3) and fourth (T4) measurements are reported and 
examined in correlation with side effects. The symptom variables are described by the terms 
used on the visual analogue scales for symptom measurements. As in Table 3.3, variables are 
described in terms of the dimension of the symptom, e.g., ―usual nausea‖ or ―worst pain.‖ 
When discussing symptoms as general concepts, terms like ―nausea‖ and ―pain‖ are used. 
Hypothesis One:  Side Effects. The null hypothesis assumed that there would be no 
differences between the groups with respect to side effect symptoms. For this study, the null 
hypothesis was rejected in favor of the alternate hypothesis. The first hypothesis assumed that 
participants who received the CBT intervention would report a reduction in side effects, 
compared to participants who only received the SOC. Parametric testing was planned, but 
was rejected at this stage because the data did not meet criteria for parametric testing. Mann-
Whitney U and Wilcoxon rank sum testing were performed to determine between-group 
differences on both the VAS symptom data and the SF-36 data for T3 and T4. The results 
appear in Tables 4.6 and 4.7. Analysis of the means between groups did not show radical 
differences between symptom scores before and after imputation analysis was performed.  
Tables 4.6 and 4.7 display the results of the Mann-Whitney U exact test.  One-tailed 
testing for significance was used. All of these results demonstrated moderate effect sizes 
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ranging from .41 to .52. Usual fatigue scores in the experimental group (Median [Mdn] = 
42.00) were significantly lower than in the control group (Mdn = 60.00) at T3, U = 12.50, z = 
-2.01, r = -.47, p < .05).  Worst fatigue scores in the experimental group (Mdn = 59.00) were 
significantly lower than in the control group at T3 (Mdn = 73.00), U = 15.50, z = -1.16, r = -
.40, p < .05).  No significant differences between the groups resulted at T1 and T2. 
Duration of nausea scores in the experimental group (Mdn = 17.00) were significantly 
lower than in the control group (Mdn = 36.00) at T4, U = 18.00, z = -1.73, r = -.41, p < .05. 
Imputed means and variances are not radically different from true means and variances. 
Thus, the analysis changed little with imputation. Usual nausea scores in the experimental 
group (Mdn = 11.95) were significantly lower than in the control group (Mdn = 32.00) at T4, 
U = 21.00, z = -1.72, r = -.41, p < .05) only when the data were analyzed after imputation. 
There was trend toward lower usual nausea scores in the experimental group (p = .08) when 
the raw data were analyzed. The results of both analyses are shown in Tables 4.6 and 4.7 
Hypothesis One: General Health. The SF-36 was used to look at general health measures 
that could be affected by symptoms. For example, if nausea were a problem, it is reasonable 
to expect that various health domains such as vitality, social role and others could be affected. 
Moreover, the SF-36 measures domains, such as Bodily Pain that corresponds to pain as 
measured by VAS. There were no significant differences between the experimental and 
control groups.  
To summarize, the experimental group reported significantly lower scores for nausea 
and fatigue over the course of their involvement with the study after having been exposed to 
the treatment intervention compared to the control group that received only the SOC. 
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Table 4.6 
Test of Hypothesis 1: Differences Between Groups at T3 and T4 Before Imputation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: * < or =.05 level of statistical significance. **Trend toward significance at .05 level. Z 
= z-score for calculation of effect sizes. Only effect sizes for significant results have been 
calculated. 
 
 
Mann-Whitney 
U
Z
Exact Sig.       
(1-tailed)
Point 
Probability
Effect size 
(r) 
Time 3:             
2 months
Usual Nausea 28.000 -.374 .367 .017
Worst Nausea 24.000 -.801 .223 .012
Duration Nausea 23.500 -.854 .209 .015
Usual Pain 20.000 -1.217 .126 .021
Worst Pain 18.500 -1.377 .091 .009
Duration Pain 26.000 -.584 .293 .016
Usual Anxiety 30.500 -.106 .470 .022
Worst Anxiety 30.000 -.159 .459 .041
Duration Anxiety 31.000 -.053 .500 .041
Usual Fatigue 12.500 -2.013 .022* .003 -.47
Worst Fatigue 15.500 -1.695 .047* .005 -.40
Duration Fatigue 17.500 -1.485 .075 .008
Time 4:            
3 months 
Usual Nausea 21.000 -1.444 .080** .007
Worst Nausea 28.000 -.771 .233 .015
Duration Nausea 18.000 -1.733 .043* .005 -.41
Usual Pain 30.500 -.530 .313 .020
Worst Pain 35.000 -.096 .472 .019
Duration Pain 29.000 -.674 .263 .015
Usual Anxiety 31.000 -.481 .336 .034
Worst Anxiety 24.000 -1.155 .138 .020
Duration Anxiety 25.000 -1.060 .155 .011
Usual Fatigue 29.500 -.626 .279 .017
Worst Fatigue 28.500 -.723 .247 .014
Duration Fatigue 33.000 -.289 .398 .018
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Table 4.7  
Test of Hypothesis 1: Differences between Groups at T3 and T4 After Imputation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: * < or =.05 level of statistical significance. Z = z-score for calculation of effect sizes.  
 
 
Note: * < or =.05 level of statistical significance. **Trend toward significance at .05 level. Z 
= z-score for calculation of effect sizes. Only effect sizes for significant results have been 
calculated. 
 
Mann-Whitney 
U
Z
Exact Sig.       
(1-tailed)
Point 
Probability
Effect size 
(r ) 
Time 3:             
2 months
Usual Nausea
39.00 -0.133 .456 .016
Worst Nausea 35.00 -0.489 .324 .015
Duration Nausea 35.50 -0.444 .340 .016
Usual Pain 28.00 -1.104 .149 .020
Worst Pain 22.50 -1.590 .060 .006
Duration Pain 35.00 -0.487 .323 .012
Usual Anxiety 38.50 -0.177 .441 .019
Worst Anxiety 37.00 -0.309 .398 .033
Duration Anxiety 40.00 -0.044 .500 .034
Usual Fatigue 15.50 -2.209 .013* .001 -0.52
Worst Fatigue 18.50 -1.944 .026* .002 -0.46
Duration Fatigue 25.50 -1.327 .099 .008
Time 4:            
3 months 
Usual Nausea
21.00 -1.723 .045* .005 -0.41
Worst Nausea 28.00 -1.105 .143 .010
Duration Nausea 18.00 -1.988 .024* .003 -0.47
Usual Pain 30.50 -0.883 .200 .013
Worst Pain 40.00 -0.044 .492 .017
Duration Pain 29.00 -1.017 .164 .011
Usual Anxiety 37.00 -0.309 .398 .033
Worst Anxiety 29.00 -1.015 .170 .021
Duration Anxiety 29.00 -1.017 .164 .011
Usual Fatigue 35.50 -0.442 .342 .017
Worst Fatigue 31.50 -0.796 .225 .013
Duration Fatigue 40.00 -0.044 .491 .017
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Hypothesis Two. The second hypothesis predicted that participants who received the CBT 
intervention would show a difference in adherence compared to those who only received the 
SOC. The direction of such a difference was undetermined. Adherence was measured by a 
VAS (Giordano, et al., 2004) and by a three-day recall instrument (Chesney, et al., 2000). At 
three of the four measurement intervals, both measures were highly correlated. The data were 
non-normal, with both the VAS adherence scores and the 3-day recall scores skewed sharply 
to the right. Skewness changed little from when the data were examined in their raw state, 
and when the data were transformed using the sum of squares and natural logs. Participants 
were on ART an average of 200 weeks (SD 160.5) and had adherence rates approaching 
100%. Adherence was high even at the study entry with mean adherence by the VAS of 93.4 
(SD 10.86, range 70-100) and a 3-day recall of .89 (SD .17, range .67-1.00). Moreover, 
Levene’s tests of variances were not homogenous for means (necessary for parametric 
testing) (p <.05) but were homogenous for medians (p > .05) (either case is acceptable for 
non-parametric testing). Two-tailed tests of significance were used for this analysis. 
Between-group differences were non-significant and adherence rates were high for both the 
experimental and control groups during the course of the study. The null hypothesis was 
accepted. 
Hypothesis Three.  Participants who received the CBT intervention were expected to show a 
difference in CD4 and VL compared to those who only received the SOC. The direction of 
change was not hypothesized. The null hypothesis stated that there would be no difference 
between the groups with respect to CD4 and VL. For CD4 there were six complete 
observations for pre and post with the following means and SDs. Earlier it was noted that due 
to the paucity of laboratory data imputation analysis was used to generate plausible pairs of 
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Table 4.8 
Correlations Between 3-day Recall and VAS for Adherence 
Measurement 
Interval 
3DR – VAS 
r 
Significance 
Study Start 
Time 1 .81 p < .01 
1 month 
Time 2 .57 p < .05 
2 months  
Time 3 .98 p < .01 
Study Exit 
Time 4 .84 p < .01 
                    Notes: 3DR: 3-day recall; VAS: visual analogue scale. 
 
    Figure 4.2   Weeks on ART at Study Entry, by Participant Number 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes: ART: antiretroviral therapy. Actual values in weeks displayed in boxes. 
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Table 4.9 
Participant-estimated Adherence by VAS, Non-parametric Testing, Group Differences 
Notes: Kruskal Wallis test, grouping variable by assignment. Asymp. Sig.:Asymptotic 
significance. 
 
CD4 counts and viral loads. During preliminary analysis of the data the extent of missing 
data in this particular variable was observed, resulting in use of EM algorithm imputation to 
continue the analysis. One case with missing data for both CD4 and viral load in the 
experimental group was excluded.  The imputed means and standard deviations were lower 
but the patterns of means were the same.  
Table 4.10 
Descriptive Statistics of Raw Laboratory Data 
 
 
 
 
 
 
 
Note: CD4: CD4 count, VL: viral load. 
 Adherence  
VAS  
T1 
Adherence  
VAS  
T2 
Adherence  
VAS  
T3 
Adherence  
VAS  
T4 
Chi-Square 1.395 2.138 .549 3.22000 
df 1 1 1 100 
Asymp. Sig. .237 .144 .459 .07300 
N Mean SD Variance Skew Kurtosis
Starting 
CD4 13 121 1362 544.23 352.24 124069.53 1.14 1.14
Start 
Log10VL 13 1.7 2.2 1.92 0.11 0.01 0.26 3.29
Ending 
CD4 18 148 9999 2094.17 3647.37 13303302.74 1.93 1.99
Ending 
Log10VL 18 .0 2.6 1.41 0.92 0.85 -0.86 -0.98
Range
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Table 4.11  
Descriptive Statistics: CD4 Means Compared Before and After Imputation 
 
 
 Assignment Mean 
Standard 
Deviation 
N 
Before Starting CD4 Control 524.33 223.031 6 
Imputation Experiment 600.17 484.194 6 
Analysis Total 562.25 361.585 12 
 Ending CD4 Control 519.00 175.442 6 
 Experiment 579.50 424.900 6 
 Total 549.25 311.533 12 
After Starting CD4 Control 437.81 230.109 9 
Imputation Experiment 585.34 410.532 8 
Analysis Total 507.23 325.532 17 
 Ending CD4 Control 446.37 181.799 9 
 Experiment 565.56 360.212 8 
 Total 502.46 277.584 17 
 
A  post hoc power analysis indicated (Keppel, 1991)(Keppel, 1991)(Keppel, 
1991)(Keppel, 1991)(Keppel, 1991)(Keppel, 1991)(Keppel, 1991)that 54 participants in each 
group would have been needed to show the interaction between viral load by group, assuming 
no participant left the study. (P. Ricci, personal communication, May 28, 2010). 
Consequently hypothesis three could not be analyzed. The null hypothesis could be neither 
accepted nor rejected. 
Confounding variables.  Two other variables needed to be considered in the context of side-
effect symptom control in this study; the first was to account for the use of side effect-
reducing medication (SERM). The second confounding variable was how often experimental 
group participants practiced the CBT techniques taught to them during the intervention visits, 
progressive muscle relaxation therapy (PMRT), and guided imagery (GI) outside of the  
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Table 4.12  
Descriptive Statistics: Viral Load Means Compared Before and After Imputation 
 
 Assignment Mean 
Standard 
Deviation 
N 
Before Starting VL 
Absolute 
Count 
Control 74.00 .000 7 
Imputation Experiment 89.33 36.779 6 
Analysis Total 81.08 25.038 13 
 Ending VL 
Absolute 
Count 
Control 128.71 128.239 7 
 Experiment 79.17 28.046 6 
 Total 105.85 95.976 13 
After Starting VL 
Absolute 
Count 
Control 78.08 9.221 9 
Imputation Experiment 86.18 31.747 8 
Analysis Total 81.90 61.34 17 
 Ending VL 
Absolute 
Count 
Control 118.13 113.086 9 
 Experiment -2.54 225.247 8 
 Total 22.379 180.128 17 
 
 
 Assignment Mean 
Standard 
Deviation 
N 
Before Starting VL 
Log10 
Control 1.900 .0000 7 
Imputation Experiment 1.933 .1690 6 
Analysis Total 1.915 .1104 13 
 Ending VL 
Log10 
Control 1.987 .3364 7 
 Experiment 1.898 .1423 6 
 Total 1.946 .2591 13 
After Starting VL 
Log10 
Control 1.922 .0541 9 
Imputation Experiment 1.927 .1434 8 
Analysis Total 1.924 .1023 17 
 Ending VL 
Log10 
Control 1.965 .2948 9 
 Experiment 1.713 .5168 8 
 Total 1.847 .4208 17 
Notes: VL = viral load (serum viral RNA by branched chain DNA assay). 
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intervention visits. Statistical testing was performed in order to analyze whether or not either 
of these two confounders affected the results. 
The use of SERM was recorded in ―checklist‖ diaries over each of the three months 
that each participant was in the study. The use of SERM for both groups throughout the study 
is shown in Figure 4.4. There were no statistically significant differences in SERM use 
between the groups during the study.  
Multivariate testing was used to examine the relationships of each type of SERM 
(e.g., for nausea) against its effect on the relevant symptom, and whether that affected those 
differences. The main focus of this testing was on nausea, because there was significantly 
less nausea reported in the experimental group. Although there was also significant reduction 
in fatigue in the experimental group, no data were collected on SERM for fatigue, because 
there is no approved medication for fatigue. Therefore no testing for confounding effects for 
SERM and fatigue was performed. 
Practice of CBT Techniques. Multivariate analysis, again, showed no significance for 
multivariate, within-subject effects, or within-subject contrasts. The data file was split to 
exclude controls (which did not practice CBT) and bivariate analysis was performed on daily 
practice against each of the 12 symptom variables. At T3, practice frequency was 
significantly correlated with symptoms scores for usual nausea, duration of nausea, and usual 
pain (Table 4.26).  No other significant correlations were found. Practice per day of the CBT 
techniques ranged from none (zero) to approximately nine times per week (1.29); two 
different participants each were missing data for each of the measurements. 
 
 
 92 
 
 
 
 
 
  Figure 4.3 SERM Use by Participants During the Study 
 
Note: Bars display means and are grouped by measurement interval. 2 = during 
participants’ first month in the study. 3 = during second month. 4 = from end of 
second month to study exit. 
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Table 4.13  
 
Correlations Between Average Daily Practice and VAS Symptom Scores 
r Sig. r Sig.
Nausea Usual .79
* .03 .18 .66
Nausea Worst .66 .11 .54 .17
Nausea Duration .90
** .01 .35 .39
Pain Usual .77
* .04 .33 .42
Pain Worst .69 .09 .33 .42
Pain Duration .50 .25 .00 1.00
Anxiety Usual -.02 .97 .56 .15
Anxiety Worst -.23 .62 .44 .28
Anxiety Duration .05 .91 -.07 .87
Fatigue Usual .40 .38 .07 .87
Fatigue Worst .15 .75 .24 .57
Fatigue Duration .36 .43 -.23 .59
Time 3 Time 4
 
Notes. *. Correlation is significant at the 0.05 level (2-tailed). **. Correlation is significant at 
the 0.01 level (2-tailed). Positive correlations equate with symptoms increase with frequency 
of practice. Negative correlations equate with decreasing symptoms with increasing practice. 
Sig: significant.  
 
Summary of Data Analysis 
The sample was analyzed and found to be predominantly composed of white males. 
Mean time on ART was 200 weeks. Random assignment did produce otherwise equivalent 
groups with no significant differences in symptom scores, SF-36 scores, adherence, or 
clinical measures at study entry.  
Hypothesis testing was conducted using Mann-Whitney U. The experimental group 
reported significantly lower mean symptom scores on nausea and fatigue. In the first case, the 
null hypothesis asserted that there would be no difference between the experimental and 
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control groups in symptom scores. The null hypothesis was rejected. The first hypothesis, 
that participants in the experimental group would have fewer side effects, as evidenced by 
lower symptom scores, was accepted.  
In the second case, the null hypothesis asserted that there would be no difference in 
adherence between the experimental and control groups at the close of the study. No 
differences were found and the null was accepted. Mean adherence in both groups throughout 
the study exceeded 90%.  
In the third case, the null hypotheses asserted that there would be no difference 
between the experimental group and the control group on CD4 and VL. No significant 
differences were found. The null hypothesis was accepted.  
Two confounding variables were tested for their correlation with symptom scores, 
practice frequency of PMRT and GI, and use of SERM. The mean daily practice frequency 
was 1.29 times per day. Increasing practice frequency of PMRT and GI was associated with 
increasing symptom scores for nausea. The mean use of SERM per day for any symptom was 
<1 dose per day. No correlation of SERM use with symptom scores was found.  
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Chapter 5 
Discussion and Implications 
  This chapter discusses the results of the study in terms of the hypotheses that were 
proposed, limitations of the study, and implications of the results for nursing practice. Both 
the hypothesis testing and recruitment issues are then linked to theoretical discussion in 
Chapter 1. 
Discussion of the Results  
 Hypothesis One. It was expected that HIV/AIDS patients would experience 
improvements in subjective symptom complaints related to ART following CBT intervention 
over time, similar to oncology patients who had received similar CBT interventions in other 
studies (Loscalzo, 1996; Redd, et al., 2001) The first hypothesis proposed that participants in 
the experimental group would report lower side effect symptom scores compared to those in 
the control group. Participants who received the CBT intervention reported significantly less 
nausea and fatigue than those who did not receive the intervention.  
Higher levels of nausea were correlated with increasing frequency of practice of the 
CBT techniques taught to participants, progressive muscle relaxation therapy (PMRT) and 
guided imagery (GI) The positive correlation suggests that practice of CBT was associated 
with increased symptoms at one point during the study. This was an unexpected and 
paradoxical finding. Negative correlations would be expected if practice lowered symptom 
scores. No other symptom scores were positively correlated with practice in this way. Such 
an association is not consistent with the findings in other studies of CBT in anticipatory 
nausea and vomiting (Burish, et al., 1987; Burish & Jenkins, 1992; Burish & Lyles, 1979; 
Burish & Lyles, 1981; Burish & Tope, 1992; Carey & Burish, 1987; Carey & Burish, 1988; 
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Morrow, et al., 1992; Mundy, et al., 2003; Redd, et al., 2001). However Zachariae et al. 
(2007) note that autonomic sensitivity can make nausea worse when it is part of a conditioned 
response. This suggests that thinking about nausea may make it worse, for some people. In 
ART indefinite therapy that is generally less intensely emetogenic is the rule. Indeed, in this 
study, levels of nausea ranged from about 20 to less than 45 on the VAS for all aspects of 
nausea that were measured. However, standard deviations ranged from approximately 20-34, 
which means that nausea was relatively modest in many participants, and was intense, 
frequent or was of lengthy duration in a only few of the participants. It is thus difficult to link 
the results of this study to that in oncology, given that in studies of CBT and oncology 
(Arakawa, 1995, 1997; Burish & Lyles, 1979) there was much more focus on nausea. This 
would be interesting to study further.  
Hypothesis Two. It was hypothesized that the CBT intervention could have an effect 
on adherence to medications over time. The null hypothesis was accepted because no 
statistically significant differences between the groups were found. The sample results were 
examined across the duration of the study, as well as between groups.  
The adherence VAS and 3-day recall were significantly correlated with each other, 
and thus reinforced each test’s validity and reliability. What was striking about the results 
was not that the CBT intervention seemed to have no influence on adherence, but rather that 
adherence was so high throughout the study. As was discussed in Chapter 2, adherence to the 
antiretroviral regimen is considered a cornerstone of effective disease management in 
HIV/AIDS (Press, et al., 2002).  
Although adherence is generally high initially, over the course of one to two years it 
can drop to 67%--only 2/3 of patients are adherent to 95% of doses (Chesney, 2003; 
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Mannheimer, et al., 2002). Mean duration of ART in the sample of participants in the present 
CBT trial was about four years. Thus it would be expected that adherence would have 
averaged what has been reported in those other studies. As was noted in the review, 
adherence has been shown to be influenced by a variety of factors including depression 
(Boarts, Sledjeski, Bogart, & Delahanty, 2006), patients’ ideas about their illness and its 
treatment (Wilson, et al., 2002), active substance abuse (Mellins, Kang, Leu, Havens, & 
Chesney, 2003; Tanney, Naar-King, Murphy, Parsons, & Janisse, 2010) and other life factors 
such as stressful events in the home (Mellins, et al.). This study did not collect data on those 
factors, so the extent of such factors in the sample is unknown. Data on socioeconomic status 
were also not collected. One explanation for the finding of high reported adherence in both 
groups throughout the study may be that patients who manage to take ART for longer than 
two years are more likely to remain adherent. However, this is not replicated when compared 
with large, longitudinal cohort studies that have shown adherence to decline from >90% to 
80% over 4 years (Lazo et al., 2007) and to 51.8% at a mean duration of ART of 4.5 years.  
There are several possible reasons that the participants in this study reported exceptional 
adherence: selection bias, poor recollection of actual adherence, deliberate misreporting, 
lessened drug toxicity with newer agents, or better ways to treat side effects. No significant 
differences in adherence were found over time, and given the high levels reported in both 
group, it is unlikely that the sample was large enough to detect any difference.  
 Hypothesis Three: It was hypothesized that the CBT intervention could have an 
effect on laboratory measures, CD4 counts and VL. There were many missing data points, 
and both the raw data, and data based on imputed values, were described. The means, 
variance and standard deviations changed little as a result. However, owing to the wide 
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variance and large standard deviations both before and after imputation analysis, as well as 
the small sample size and low statistical power it was decided that there was insufficient data 
from which to draw conclusions. Moreover, recent evidence calls into question the current 
clinical approach that utilizes CD4 lymphocyte counts as an ―absolute‖ measure of  immune 
competence against opportunistic infection. Robustness of viral containment by CD8 
lymphocytes, natural killer (NK) activity (Alter & Altfeld, 2009),  CD4/CD8 ratio  (Forbi & 
Agwale, 2009), and expression of CD38 and the immunopathogenic factor programmed cell 
death (PD-1) (Holm, Pettersen, & Kvale, 2008) may factor more significantly than CD4 
counts alone, which themselves are subject to considerable variation due to factors other than 
virus level alone (Amatya et al., 2004).   
Limitations of the Study   
Sample Size and Composition. While the strength of the study design was that it 
tested the intervention against an untreated control group, the sample size was small. 
Although the study was fully enrolled (n = 33), only slightly over half of the enrollees 
completed the trial. The sample was overwhelmingly male. Females now make up some 26% 
of the population with HIV/AIDS (CDC_MMWR, 2005), so the sample did not adequately 
represent the sex distribution in the general population. The sample was also overwhelmingly 
made up of white men. This tends to limit the clinical applicability to similar populations. 
However, given the moderate effect size of CBT interventions in other studies and this one, 
and the greater likelihood of type II error in smaller samples, the multiple statistically 
significant individual comparisons in VAS scores found in favor of the intervention in this 
study are remarkable, since multiple effects in favor of the experimental group’s nausea and 
fatigue scores was observed despite the actual effect sizes (<1.00) observed in the sample.  
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Adherence. Interestingly, the participants in both the experimental group and the 
control group had a very high adherence to ART. With respect to the second hypothesis, any 
potential impact of CBT on adherence would have been difficult to improve upon simply 
because of the already very high adherence reported in this study.  Clinically significant 
improvement in adherence was probably not possible, even if the CBT intervention was  
found to have a statistically significant effect. 
Variations in Laboratory Testing and Missing Laboratory Data. Most CD4 
counts and viral loads were performed by the same medical center laboratory, but not all 
were.  This introduced a confounding variable in the analysis of that data.  
Missing data. Much missing laboratory data led to using an algorithm to generate 
imputed values for missing CD4 counts and viral loads. Several participants simply did not 
have their laboratory tests done as requested by their medical providers. No data were 
collected on why this was the case. The clinical staff suggested that despite their best efforts, 
such missed testing is commonplace. 
Premise of the Study and Issues in Recruitment of Participants 
 As was noted in Chapter 1, the impetus for this study developed from the clinical 
experiences of the investigator while working with HIV/AIDS 1996-2002 and involved 
patients who fared poorly on ART due to intense and intractable side effects. Furthermore, an 
exhaustive review of the literature showed that little research had been done in attempting to 
mitigate the side effects of ART in HIV/AIDS patients. This study was conducted to gain 
further insight into the effects of CBT on adverse symptomatology and thus, fill this gap in 
the literature. This study is a step toward filling that gap. 
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 The low rate of recruitment was reported in Chapter 4 from data that tracked each 
participant’s progress through the study. However, no data were collected about why some 
people chose not to participate. Limited data were collected on why people withdrew. Many 
patients were potentially eligible for the study, as they were on ART. The clinic database, 
updated at each patient visit, showed that approximately 90% of those patients eligible to be 
on ART were prescribed ART (Personal communication, J. Zurlo, March 19, 2007). Little 
had changed by the time the study commenced in September 2008, and about 90% of the 
clinic’s population was on ART (Personal communication, D. Greenawalt, September 2, 
2008). Those few patients in the infectious disease clinic who were not on medications, fell 
into two general categories: 1) they were ineligible for treatment based on the guidelines for 
VL and/or CD4 count (Panel_on_Antiretroviral_Guidelines_for_Adults_and_Adolescents, 
2009); or, 2) were ineligible for ―other reasons,‖ including active substance abuse (Personal 
communication, D. Greenawalt, September 2, 2008). Screening by clinic staff eliminated 
many patients due to  1) lack of reports of side effect symptoms; 2) belief that the person 
lived ―too far away‖ to participate; or, 3) that the patient ―would not be good‖ for the study. 
This reduced the pool of patients for consideration of enrollment. 
 Admission to the study was offered to those patients who the staff had screened for 
participation as noted above.  Patients were not questioned about why they chose not to 
participate, as this could be interpreted as coercion. One of the hallmarks of ethical research 
is non-coercion (Polit & Beck, 2004), and the investigator wished to avoid putting patients 
―on the spot‖ when they are already in the vulnerable position of having HIV/AIDS. 
However, some patients volunteered their reasons for non-participation: 
 ―I have too much going on right now.‖ 
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 ―I have transportation issues.‖ 
 ―I don’t think my problems are from the medicine.‖ (From personal communications 
kept in author’s notes and not specifically attributed for anonymity, September 9, 
2008 through June 10, 2009.) 
 Scheduling with the psychologist for the intervention was a major concern expressed 
with respect to the first two reasons stated. For those participants who were scheduled and 
completed the series of three visits with the psychologist expressed very positive statements 
about the experience and the techniques they learned. Nevertheless, scheduling not only 
appeared to interfere with keeping medical appointments (Personal communication, D. 
Greenawalt, April 28, 2009), but appeared to have some bearing on whether patients felt they 
had the time to be in the study.  
 The third statement concerning patients who felt their symptoms were not medication 
related was discussed earlier. It was assumed that patients know the difference. However it is 
possible that they did not always know what momentary complaints were related to: HIV, co-
morbidities, or side effects. In summary, in addition to the restrictive selection by the clinic 
staff, low recruitment may be related to patients’ concern about scheduling and availability 
for the intervention, as well as lower reported side effect symptoms than expected.   
Theoretical Framework 
  The theoretical framework for this study was based on cognitive control of autonomic 
responses which would lead to lessening of autonomic symptoms caused by patients’ 
experience with ART. In the first chapter, anxiety was discussed as being both a symptom 
and an amplifier of the discomfort associated with other symptoms such as nausea/vomiting, 
pain, and fatigue. The literature review discussed the success seen in reducing symptoms 
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associated with antineoplastic therapy in cancer treatment. It was reasonable to theorize that 
such CBT-related symptom reductions would apply in ART as well. In this study the 
significant effects of the CBT intervention on side effects symptoms are consistent with 
previous research, although the sample composition suggests limits to generalization to all 
HIV/AIDS patients on ART.  
In this study, anxiety and pain were not significantly different between the groups. As 
noted in Chapter One anxiety is itself a symptom, and it has been theorized that anxiety also 
amplifies other symptoms, such as pain (Adams & Field, 2001; Adams, et al., 2006; Colloca 
& Benedetti, 2007), nausea (Burish & Carey, 1986), and fatigue (McCann & Boore, 2000). It 
was expected that the findings of any decreased symptom—and in this study nausea and 
fatigue were decreased in the experimental group—would co-occur with findings of 
decreased anxiety, but this was not observed. It is possible that small sample size led to an 
inability to detect changes in anxiety. It is also possible that anxiety has variable effects on 
other side effect symptoms, and that CBT may modify such symptoms without also 
modifying anxiety, especially in participants whose anxiety was low and other symptoms 
were high. The sample size was not large enough to detect such interactive effects. The 
experimental group failed to benefit with reduced anxiety from the CBT intervention, and 
this runs contrary to both the literature and the theory (Hunot, Churchill, Silva de Lima, & 
Teixeira, 2007). They did, however, benefit from the intervention with respect to nausea and 
fatigue which is concordant with the literature on CBT in oncology (Carey & Burish, 1988; 
Morley, et al., 1999; Mundy, et al., 2003; Redd, et al., 2001).  
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Suggestions for Further Research  
 The results of this study suggest that CBT can help highly medication-adherent, male 
HIV/AIDS patients on ART experience less nausea and fatigue, after only three CBT 
sessions that include progressive muscle relaxation therapy (PMRT) and guided imagery 
(GI), techniques that can be practiced outside the clinic, as patients feel the need to do so. It 
was noted in Chapter Two that to date, no study had been published that tested 
individualized, brief-contact CBT as a means of reducing side effect symptoms from ART. 
Studies of CBT in symptom management have tended to employ a larger number of 
therapeutic encounters. This is the only study that employed such a small number of 
therapeutic encounters. The results of this study suggest that further exploration of brief-
contact CBT-type interventions for symptom reduction should be explored further. 
A larger study could be employed to examine the effects of CBT on symptom 
reduction in women as well as men, in patients who are less adherent to ART, and in a wider 
array of socio-cultural/ethnic groups. Further, a larger study enrolling more participants 
might detect similar positive effects with respect to pain and anxiety. It would be useful to 
expand the planned analysis of a larger sample to explore how individual practice of CBT 
techniques influences symptom intensity, frequency, and duration, since there was positive 
correlation between CBT practice and nausea. Although significant, this correlation may have 
been by chance, and a larger study, designed to better detect such relationships, could provide 
further clarity. 
 The recruitment and dropout rates, as well as anecdotal reports from candidates for 
and participants in this study suggest that designing a larger study to recruit patients living 
with HIV/AIDS to further study the effects of CBT on symptoms might not be practical 
 104 
 
without expanding enrollment to include multiple sites. Despite having access to some 600+ 
patients, only 18 completed the study. Although it is possible enlarging the pool of potential 
participants in a multi-center trial would improve sample size, it was also true that clinic staff 
controlled who was enrolled. Antiretroviral therapy to treat HIV disease has been in 
continuous development since the 1980s, and following the success of multi-class antiviral 
therapy in the mid-1990s, regimens have been improved with corresponding decreases in side 
effects  (Panel_on_Antiretroviral_Guidelines_for_Adults_and_Adolescents, 2009). Since this 
is the case, fewer patients may benefit from CBT employed for the purpose of reducing side 
effect symptoms. It is also possible that such symptoms are more burdensome early in ART, 
and this study was not designed to select for those individuals. A follow up study might target 
only patients on a new regimen.  
Implications for Nursing Practice 
The findings of this study lend support to the idea that a brief series of CBT sessions 
can help to reduce symptom discomfort, at least for nausea and fatigue in HIV/AIDS patients 
taking ART. In this sample, medication therapy is of life long duration.  In long term ART, 
symptoms can continue indefinitely as well. Nevertheless and despite a limited array of 
change, significant changes were observed in the small sample used in this study. Moreover, 
the intervention itself displayed no evidence of harm. In general CBT carries a low risk of 
adverse effects when the sessions are focused on reducing autonomic arousal and inducing 
relaxation for beneficial effects (J. S. Beck, 1995). Thus, given even the modest findings in 
this study and the relative safety of CBT as practiced in this study, it is reasonable for nurses 
to consider CBT interventions for HIV/AIDS patients who suffer from nausea and/or fatigue 
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as while on ART. The brevity of the contact with CBT in this study creates a framework for 
in-clinic trainings by nurses familiar with CBT methods like those used in this study.  
Conclusions 
In this study CBT was delivered in a small dose of three visits by a behavioral 
interventionist to HIV/AIDS patients with any of four functional symptoms associated with 
ART including fatigue, pain, nausea and anxiety. In this small clinical trial, the experimental 
group reported significantly lower scores, compared to the control group, over time for some 
measures of fatigue and nausea, but not pain or anxiety. The study was limited by low 
enrollment, in part due to the lack of symptoms reported by patients as newer ART drugs 
have been developed and marketed. A high dropout rate occurred and may have been due to 
several causes including the difficulty of scheduling time with the behavioral interventionist, 
as well as medical visits, which were separate from the study visits. Even with this small 
sample, the study’s results suggest that CBT has some benefit for treating fatigue, and nausea 
in these patients.   Cognitive-behavioral therapy, as the study intervention, had no effect on 
the biological parameters of CD4, viral load, or adherence to therapy. However adherence for 
this study sample was reported overall to be higher than has been reported in HIV/AIDS 
literature. Interestingly, in this study CD4 and VL were not correlated, nor was adherence 
correlated with CD4 or VL. Moreover, the majority of participants had VLs that were 
―undetectable‖ with values below the cutoff of 75 copies of viral RNA per mL. Little else 
could be done to improve upon adherence and virus levels in this sample. There may have 
been unintentional bias in how clinic staff prescreened patients for enrollment, and may have 
represented the bias of the clinic providers who identifying individuals who they ―thought‖ 
would be appropriate for the study. The results of this study provide more insight into the 
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management of the symptoms associated with ART in HIV patients, and suggest that CBT 
may be a useful clinical tool to help reduce side effects of ART, at least in some patients. 
 The results suggest that a larger study might be worthwhile. A follow up trial might 
focus on those patients most likely to have symptoms, patients who begin new regimens. The 
effects of individual practice of the CBT techniques used in this study by patients (having 
been taught those techniques by a therapist) might be studied, since individual practice was 
unexpectedly correlated with increasing nausea. The effects seen from the small dose of CBT 
and the problems encountered with recruiting and scheduling for the separate intervention 
suggest that bringing such an intervention into the clinic and parallel with medical treatment 
could prove valuable. This could easily be incorporated into nursing practice.  Non-drug 
interventions that fit into care models of nursing and skill set offer an important avenue to 
reducing patient symptoms and improving their quality of life. The findings from this study 
offer evidence that simple CBT techniques are useful for achieving improvements in patient 
comfort, and can serve as a starting point for a promising line of research. 
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APPENDIX A 
 
DEMOGRAPHIC DATA FORM 
  
 
 
 
Instructions: circle or complete each item as it applies 
1. Biologic sex  
male [1] 
female [2] 
endocrine transsexual process, MF [3] 
endocrine transsexual process, FM [4] 
surgical transsexual process, MF [5]  
surgical transsexual process, FM [6] 
 
2. Racial/ethnic group  
Caucasian [1] 
Caucasian Hispanic [2] 
African American [3] 
African [4] 
African Hispanic [5] 
Other Hispanic [6] 
East Asian [7] 
South Asian [8] 
Pacific Islander [9] 
 
3. Understand/read/speak English?  
yes [1] 
no [2] 
4. Age (number): ___________ 
[number] 
5. Duration of ART weeks: ______________  
                                        [number] 
 
6. Does candidate suffer from any of the following that are related to ART?  
Nausea &/or vomiting [1]    Fatigue [3] 
Pain [2]      Anxiety [4] 
 
 
PARTICIPANT NUMBER 
Initials – Birthdate – 2-digit sequence 
number 
 
 
DATA COLLECTOR   
 
DATE 
 
 
 
Medication 
Side Effect Study 
Demographic Data 
Form 
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APPENDIX B 
MEASUREMENT INSTRUMENTS 
Facsimiles of the instruments appear on the following pages.
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   DUQUESNE UNIVERSITY        School of Nursing 
      600 FORBES AVENUE      PITTSBURGH, PA 15282 
 
INSTRUCTIONS 
 
We would like to know how you feel about a few ordinary things today. There are several 
things listed on the following pages. Each thing is a symptom or a feeling you may 
experience while on HIV medication. Each question asks you about how strong the feeling or 
symptom is, or how long you have been experiencing it. With each question there is a line 
that looks like this: 
 
 
                                                                      MOST 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                            
The LEAST or NONE 
 
 
The bottom of the line is the lowest, or least amount. The top is the most, strongest, or worst 
feeling. 
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And each line will have words that describe your feelings about the thing, a rough number of 
the thing (like a few or many), or how long it lasts. Like this example: 
 
     
FOOD: how tasty was your last meal?  
 
  
 
 
 
   The best meal ever                                                                               The best meal ever 
 
 
                 
 
 
 
 
 
 
 
 
 
              
 
            Not at all                                                                                              Not at all 
 
 
 
 
 
That’s all there is to it! Please turn to the next page and complete the items. If you have any 
questions, feel free to ask the research associate for help. 
For each item, use the 
red pen to make a 
mark on the line that 
most describes the 
LEVEL of the thing or 
how long it lasts. Like 
this: 
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These three questions are about NAUSEA, ―sickness in the stomach,‖ or ―queasiness‖ 
 
 
 
The worst ever   The worst ever           All the time 
 
 
 
 
 
 
 
 
         
         None                                    None                                   None 
 
PARTICIPANT NUMBER  
 
DATE OF COMPLETION  
 
MEASUREMENT NUMBER  
 
DATA COLLECTOR       
 
 
Medication 
Side Effect Study 
VAS Page 1 
 
1. Mark the line 
with the usual 
amount of 
nausea in the 
last month 
2. Mark the line 
with the worst 
amount of 
nausea in the 
last month 
3. Mark the line 
with the length of 
time you typically 
felt nausea in the 
last month 
Page Over 
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These three questions are about PAIN of any sort 
 
 
 
 
 
 
 
 
 
 
 
 
The worst ever                  The worst ever                        All the time 
 
 
 
 
 
 
 
 
 
         None                                    None                                   None 
 
 
1. Mark the line 
with the usual 
amount of pain in 
the last month 
2. Mark the line 
with the worst 
amount of pain in 
the last month 
3. Mark the line 
with the length of 
time you typically 
felt pain in the 
last month 
Next Page 
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VAS Page 2 
 
 
 
 
 
These three questions are about ANXIETY, ―nervousness,‖ or ―worry‖  
 
 
 
 
 
The worst ever                    The worst ever                       All the time 
 
 
 
 
 
 
 
 
 
            None                                   None                                    None  
  
 
 
PARTICIPANT NUMBER  
 
DATE OF COMPLETION  
 
MEASUREMENT NUMBER         
 
DATA COLLECTOR       
 
1. Mark the line 
with the usual 
amount of 
anxiety in the last 
month 
2. Mark the line 
with the worst 
amount of 
anxiety in the last 
month 
3. Mark the line 
with the length of 
time you typically 
felt anxiety in the 
last month 
Page Over 
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These three questions are about FATIGUE, ―tiredness,‖ or ―no energy‖ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The worst ever            The worst ever             All the time 
 
 
 
 
 
 
 
 
 
        None                                   None                                    None 
 
1. Mark the line 
with the usual 
amount of fatigue 
in the last   
month 
2. Mark the line 
with the worst 
amount of fatigue 
in the last   
month 
3. Mark the line 
with the length of 
time you typically 
felt fatigue in the 
last month 
Go onto the next page 
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INSTRUCTIONS 
Your packet contains a calendar and the research associate has marked the calendar with your 
study starting date. During the study, each time you practice the methods in your 
personalized recording, mark that on the day that you did so. For example if you practiced 
once on Thursday, March 20
th
, Saturday March 22
nd
, and Wednesday, March 26th then you 
would mark the calendar like this: 
 
Sunday Monday Tuesday Wednesda
y 
Thursday Friday Saturday 
16 
 
 
 
17 18 19 20 
 
Practice 
21 22 
 
Practice 
23 
 
 
 
24 25 26 
 
Practice 
27 28 29 
 
That’s all there is to it! You may practice your recorded exercises as often as 
you feel it is necessary to maintain your health. If you have any questions, 
contact a research associate at (717) 948-6513. 
 
  
PARTICIPANT 
NUMBER 
 
 
DIARY DATES FROM 
 
 
SET ____ OF ____ 
TO 
 
DATA COLLECTOR 
NUMBER 
 
 
 
Medication 
Side Effect Study 
Practice Sessions 
Diary 
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APPENDIX C 
RECORDING SHEETS FOR THE USE OF SERM 
Facsimiles of this instrument appear on the following pages.
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INSTRUCTIONS 
This is a diary to help you let us know how many doses of medicine you have used 
to reduce side effects. Just fill in the date you took the medicine. Go from top to 
bottom in each column, and when you run out of space, start at the top of the next 
column. If you take more than 1 dose on a given day, you can just make a 
checkmark below that date. Like this: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If you run out of room, we have included a blank diary for you to fill in as needed. 
 
 
 
 
 
PARTICIPANT 
NUMBER 
 
 
DIARY DATES FROM 
 
 
SET ____ OF ____ 
TO 
 
DATA COLLECTOR 
NUMBER 
 
 
 
Medication 
Side Effect Study 
Medication Diary 
 
 
Medicines for NAUSEA 
Just write in the 
date when you 
take your first 
dose that day 
Then just make 
a check mark if 
you take any 
more doses that 
day 
There is a diary chart for 
each type of side effect 
medicine we need to 
know about 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ere is a diary chart for 
each type of side effect 
medicine we need to 
know about 
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Medicines For PAIN 
      
      
      
      
      
      
      
      
      
      
      
      
Medicines For NAUSEA, ―sickness in the stomach‖ or queasiness 
      
      
      
      
      
      
      
      
      
      
      
Protocol #  000-0000-XXX : PARTICIPANT 
NUMBER  
 
 
DIARY DATES FROM TO 
DATA COLLECTOR NUMBER  
2 
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Medicines For ANXIETY or nervousness 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If you need more pages, please contact a research associate. Thank you! 
Protocol #  000-0000-XXX : PARTICIPANT 
NUMBER  
 
 
DIARY DATES FROM TO 
DATA COLLECTOR NUMBER  
      
      
      
      
      
      
      
      
      
      
      
      
3 
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APPENDIX D 
INFORMED CONSENT 
A facsimile of this document appears on the following pages. 
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APPENDIX E 
CONFIDENTIALITY AGREEMENT 
DUQUESNE UNIVERSITY 
         600 FORBES AVENUE      PITTSBURGH, PA 15282 
 
CONFIDENTIALITY AGREEMENT FOR: Clinical Trial of Cognitive-
Behavioral Therapy to Reduce Antiretroviral Side Effects  in HIV Patients,  
Primary Investigator, R. Eric Doerfler, CRNP, PhD(c) 
 
_____________________________________  _____________________________________ 
Name of Team Member    Role 
 
By signing below I acknowledge that I will be working as a research team member, and that 
representing such, I will have access to sensitive medical/health information about participants in this 
study. Some of this information relates to the HIV status and mental health status of research study 
participants. I understand that all health information is protected by the U.S. Health Insurance 
Portability and Accountability Act of 1996 and applicable laws of the Commonwealth of 
Pennsylvania concerning HIV status, mental health, and substance abuse.  
 
I agree to maintain the confidentiality of records and to adhere to the protocols for the security of 
paper and electronic data, included in the study proposal approved by the Duquesne University 
Institutional Review Board and the Office of Research. 
 
If I identify a health concern of or hazard for a participant I understand that I am to disclose my 
concern to the primary investigator and the participant’s treating clinician and/or nurse. 
 
This agreement remains in force after the conclusion of the study and will be kept on file with the 
primary investigator in accordance with applicable privacy laws and regulations. 
 
 
_____________________________________  ___________________ 
Signature of Team Member    Date 
 
______________________________  __________________ 
Witness       Date 
 
 
